XARELTO Media Monitoring – Week of 01-08-16

Client Attorney Privileged/Attorney Work Product/At Request of Counsel

Plaintiff Attorney Press Releases

1. Xarelto Lawsuit Plaintiffs Look Forward To January Bellwether Case Selection

   Dec 18, 2015 | Blood Thinner Help

   By Joseph Osborne
   
   
   BloodThinnerHelp.com reports on announcements that case selection for lawsuits consolidated in Xarelto bleeding lawsuits under multidistrict litigation number 2592 will begin on January 11th of 2016. This litigation is being overseen by the Honorable Judge Eldon Fallon in the Eastern District of Louisiana. Today, they number over 2,200 complaints, all containing similar allegations against Bayer AG and Janssen Pharmaceuticals’ anticoagulant drug, Xarelto.
2. Xarelto Lawsuit Multidistrict Litigation Moves Forward Since Establishment 1 Year Ago

   Dec 21, 2015 | Blood Thinner Help

   By Joseph Osborne
   
   
   BloodThinnerHelp.com reports today on the recently-increasing numbers of lawsuits filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals. The lawsuits were consolidated one year ago in December of 2014, by the U.S. Judicial Panel for Multidistrict Litigation. This consolidation, which formed multidistrict litigation number 2592, was possible due to the similarities between the over 2,200 lawsuits filed in federal court. Consolidations are done to fast-track the litigation process, helping to avoid different rulings from multiple judges, and duplicate discoveries. Additionally, this consolidation helps those involved to conserve both time and finances.
3. Xarelto Lawsuit Plaintiffs Note Investigation Of European Regulators Into Xarelto Clinical Trial

   Dec 21, 2015 | Blood Thinner Help

   By Joseph Osborne
   
   
   BloodThinnerHelp.com reports on an investigation into Xarelto clinical trials by European regulators. This investigation follows a recent surge in lawsuits filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals commonly alleging that use of the blood-thinner can cause dangerous uncontrollable bleeding events.
4. Xarelto Lawsuit Plaintiffs Note Study Linking Drug To Stomach And Eye Bleeding

   Dec 22, 2015 | Blood Thinner Help

   By Joseph Osborne
   
   
   BloodThinnerhelp.com reports on studies which appear to point to data bringing up questions surrounding the safety of blood-thinner Xarelto, produced by manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson). The study indicates a potential increase in risk of stomach bleeds and eye-hemorrhaging for patients using the drug.
5. Xarelto Lawsuit Plaintiffs To Begin Bellwether Trial Selection In Early 2016

   Dec 23, 2015 | Blood Thinner Help

   By Joseph Osborne
   
   
   BloodThinnerHelp.com reports on the scheduled case selection for lawsuits consolidated in Xarelto multidistrict litigation number 2592. The selection is currently scheduled to begin in early 2016, specifically on January 11th. Plaintiffs involved are looking forward to seeing things progress. The litigation is being overseen by Judge Eldon Fallon in the Eastern District of Louisiana. Today, Xarelto lawsuits consolidated in the MDL number over 2,200, and all contain similar allegations against Bayer AG and Janssen Pharmaceuticals’ blood thinner.
6. Xarelto Lawsuit Claims Ohio Woman’s Severe Gastrointestinal Bleed Was Caused By The Drug

   Dec 24, 2015 | Blood Thinner Help

   By Joseph Osborne
   
   
   BloodThinnerHelp.com reports on a lawsuit filed against the manufacturers Bayer AG and Janssen Pharmaceuicals (a division of Johnson & Johnson), in regard to their blood-thinning drug, Xarelto. The plaintiff claims that the drug caused her severe gastrointestinal bleeding.
7. Xarelto Lawsuit Plaintiffs Note Questioning of Trial Results Due To Defective INR Device

   Dec 28, 2015 | Blood Thinner Help

   By Joseph Osborne
   
   
   BloodThinnerHelp.com reports on recent news from Reuters which impacts the lawsuits filed against manufacturers of blood-thinner Xarelto. It was learned that both U.S. and European drug regulators have begun to research whether a defective blood-clotting test device may have changed the outcome of certain trial results on the drug.
8. Xarelto Lawsuit Alleges Manufacturers Are Liable For Life-Threatening Injuries Caused By Drug

   Dec 28, 2015 | Blood Thinner Help

   By Joseph Osborne
   
   
   BloodThinnerHelp.com reports on a lawsuit filed against the manufacturers of blood thinner Xarelto. The suit was filed in the United States District Court for the Southern District of Ohio on October 5th of 2015. It was filed by a husband and wife who are from Morrow County, Ohio.The couple alleges that Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) are responsible for the serious and life-threatening injuries experienced by the wife. Together, they are seeking over $50,000 for medical bills to treat her injuries.
9. Xarelto Lawsuit Alleges Texas Woman’s Life-Threatening Internal Bleed Caused By Drug

   Dec 28, 2015 | Blood Thinner Help

   By Joseph Osborne
   
   
   BloodThinnerHelp.com reports on the details of a lawsuit which was filed in the Eastern District of New York by a woman from Texas. The woman alleges that Xarelto manufacturers Janssen Pharmaceuticals, (a division of Johnson & Johnson), and Bayer AG failed to adequately warn consumers about the dangers associated with their blood thinning drug. Her complaint was filed in a federal court under number 1:14-cv-04524, but was later transferred, as Xarelto cases were consolidated to form multidistrict litigation number 2592 in Louisiana.
10. Xarelto Lawsuit Increase Reported In Philadelphia Court Of Common Pleas

    Dec 29, 2015 | Blood Thinner Help

    By Joseph Osborne
    
    
    BloodThinnerHelp.com reports on the steady increase of lawsuits filed against Bayer AG and Janssen Pharmaceuticals in connection with their blood thinning drug Xarelto. Today, lawsuits filed in the Philadelphia Court of Common Pleas in Pennsylvania number around 500 cases. This number has dramatically risen since September, when a reported 300 cases were involved. Additionally, cases filed against the drug in federal court have been consolidated to form multidistrict litigation number 2592 by the U.S. Judicial Panel on Multidistrict Litigation.
11. Xarelto Lawsuit Plaintiffs Blame Drug For The Death Of Their Family Members

    Dec 29, 2015 | Blood Thinner Help

    By Joseph Osborne
    
    
    BloodThinnerHelp.com reports on a lawsuit filed by a group of 10 residents from multiple states who are similarly suing pharmaceutical manufacturers, allegeing that blood thinner Xarelto has caused their family members some very dangerous and even fatal side effects.
12. Xarelto Lawsuit Plaintiffs Look Forward To Upcoming Bellwether Trials

    Dec 29, 2015 | Blood Thinner Help

    By Joseph Osborne
    
    
    BloodThinnerHelp.com reports on the announcement of Bellwether trial dates for the Xarelto multidistrict litigation number 2592. The consolidated cases will be overseen in the Eastern District of Louisiana by the Honorable Judge Eldon Fallon. Recently released court documents indicate that the first two bellwether trials are scheduled to be heard on February 6th, 2017 and March 13th of 2017, and the final two bellwether trials are scheduled to be heard on April 24th and May 30th of 2017. As 2016 approaches, plaintiffs prepare for bellwether selection from a pool of 40 cases. Those involved look forward to seeing things continue to progress.
13. Xarelto Lawsuit Plaintiffs Note Dangerous Risk Of No Antidote For Blood Thinner

    Dec 30, 2015 | Blood Thinner Help

    By Joseph Osborne
    
    
    BloodThinnerHelp.com reports on a fact that has come up frequently in the ever-increasing number of lawsuits filed against manufacturers of Xarelto: the lack of antidote available for the drug. Plaintiffs allege that this is an example of extreme negligence on the part of manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of pharmaceutical giant Johnson & Johnson); one that can cause dangerous and even fatal problems to occur in patients.
14. Xarelto Lawsuit Plaintiffs Claim Blood Thinner Advertisements Are Misleading

    Dec 31, 2015 | Blood Thinner Help

    By Joseph Osborne
    
    
    BloodThinnerHelp.com reports on recent advertisements for blood thinning drug Xarelto, manufacturered by Bayer AG and Janssen Pharmaceuticals, (a division of Johnson & Johnson). Although the anticoagulant is the subject of over 2,800 lawsuits in federal court multidistrict litigation, these advertisements seem as prevalent and persistent as ever.
15. Xarelto Lawsuit Plaintiff Blames Negligence Of Blood Thinner Manufacturers For Husband’s Death

    Jan 4, 2016 | Blood Thinner Help

    By Joseph Osborne
    
    
    BloodThinnerHelp.com reports on a lawsuit filed which highlights the dangerous side effects connected to anticoagulant Xarelto. This lawsuit, joined with many others, is consolidated in multidistrict litigation number 2592 by the U.S. Judicial Panel on Multidistrict Litigation. The MDL, created to help simplify and fast-track the litigation, is being overseen by the Honorable Judge Eldon Fallon in the Eastern District of Louisiana.
16. Philadelphia Court Of Common Pleas Reports Xarelto Lawsuit Increase In Mass Tort Group

    Jan 6, 2016 | Blood Thinner Help

    By Joseph Osborne
    
    
    BloodThinnerHelp.com reports on the continued increase of lawsuits filed against Bayer AG and Janssen Pharmaceuticals which discuss the blood thinner they manufacture: Xarelto. Today, lawsuits filed in the Philadelphia Court of Common Pleas in Pennsylvania have reportedly surpassed 500 cases. This number has significantly grown since September of 2015, at which point a reported 300 cases had been filed.
17. British Medical Journal Xarelto Study Cited In Arguments Of Xarelto Lawsuit Plaintiffs

    Jan 6, 2016 | Blood Thinner Help

    By Joseph Osborne
    
    
    BloodThinnerHelp.com reports on studies surrounding blood thinner Xarelto. Xarelto is an anticoagulant which launched in the U.S. market with initial tremendous success. The U.S. Food and Drug Association approved the drug in 2011, intending it to reduce the risk of strokes and blood clots for patients healing from hip or knee replacement surgeries. After its initial approval, Xarelto was also expanded to treat deep vein thrombosis and pulmonary embolism, and was also used preventatively to treat patients with atrial fibrillation.
18. Xarelto Lawsuit Alleges Drug Caused Georgia Man's Internal Bleeding Death

    Jan 6, 2016 | Blood Thinner Help

    By Joseph Osborne
    
    
    BloodThinnerHelp.com reports on a lawsuit now joining the over 2,800 cases federally filed in the Xarelto MDL. This particular case was filed in the Eastern District of Louisiana under complaint number 2:15-cv-00885. It was filed for a Georgia man who had passed away by his son. Allegedly, the man had died due to internal bleeding caused by Xarelto, so the son filed suit against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson).
19. Xarelto Lawsuit Alleges Blood Thinner Caused Severe Gastrointestinal Bleed For Ohio Woman

    Jan 6, 2016 | Blood Thinner Help

    By Joseph Osborne
    
    
    BloodThinnerHelp.com reports on another lawsuit which was filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson). The plaintiff involved claims that the blood thinning drug caused her dangerous and severe gastrointestinal bleed, which has left her with long-term medical needs.
20. Xarelto Lawsuit Plaintiffs Note JAMA Ophthalmology Studies Linking Drug To Dangerous Bleeds

    Jan 8, 2016 | Blood Thinner Help

    By Joseph Osborne
    
    
    BloodThinnerhelp.com reports on several studies which point to data that brings up questions surrounding the safety of blood thinning drug Xarelto. The anticoagulant is produced by manufacturers Bayer AG and Janssen Pharmaceuticals (a division of pharmaceutical giant Johnson & Johnson). The studies indicate a link to dangerous bleeding, including stomach bleeds and eye-hemorrhaging episodes to those who use Xarelto.

Plaintiff Attorney Blog Posts

21. FDA Approval of Xarelto May Have Been Based on False Data

    Dec 18, 2015 | Drug Reporter

    By Dawn Snyder
    
    
    Thousands of Xarelto users have brought federal lawsuits against the drug’s manufacturers alleging that the anticoagulant caused uncontrollable bleeding and severe injuries.
22. Xarelto Bleeding Lawsuits in MDL Hit 2,400

    Dec 18, 2015 | AboutLawsuits.com

    By Irvin Jackson
    
    
    According to a recent case list released by the U.S. Judicial Panel on Multidistrict Litigation (JPML), there are currently at least 2,400 Xarelto lawsuits pending throughout the federal court system, which all involve similar allegations that users of the controversial anticoagulant suffered uncontrollable bleeding or other problems.
23. Xarelto Bleed Injury Timeline Updates and Patient Information

    Dec 20, 2015 | Prescription Drug Injuries

    By Lieff Cabraser
    
    
    Xarelto was released in July 2011 to prevent blood clots in patients undergoing knee and hip surgeries, and its use was then expanded to include patients with irregular heartbeats or facing likely lung and leg blood clots. It was also used to prevent clots in some people with atrial fibrillation.
24. NJ Man Sues Drug Companies Over Xarelto Side Effects

    Dec 21, 2015 | Righting Injustice

    By Jennifer Walker-Journey
    
    
    A New Jersey man is suing the makers of the blood thinner Xarelto claiming the drug companies did not warn the public about life threatening side effects.
25. Xarelto Lawsuit: Georgia Woman Claims Serious Internal Bleeding Injury

    Dec 21, 2015 | Top Class Actions

    By Ashley Vanover
    
    
    A Xarelto bleeding lawsuit was filed against drug manufacturers Bayer Healthcare and Janssen Pharmaceuticals alleging they failed to provide adequate warnings about the safety risks associated with the use of the popular blood thinner.
26. More Lawsuits and Clinical Research Involving Xarelto

    Dec 21, 2015 | Xarelto Lawyer

    Rivaroxaban, the anticoagulant medication that is more commonly known as Xarelto, continues to make legal and medical headlines in 2015.
27. Xarelto Bellwether Update – Lawyer Referral

    Dec 21, 2015 | Pravati Networks

    United States District Judge Eldon Fallon is overseeing the Xarelto Lawsuit bellwether trials. Fallon issued a recent order stating that a group of 40 filed lawsuits will be selected in January 2016. After the selection the first 2 of 4 bellwehter trials will take place in the U.S. District Court of the Eastern District of Louisiana on February 6th, 2017, and March 13th, 2017. The third Xarelto bellwether trial is to be heard in Mississippi on April 24th, 2017, while the fourth and final bellwether trial will be heard in Texas on May 30th, 2017.
28. Blood Thinner Lawsuit

    Dec 22, 2015 | My Drug Justice

    By Baron & Budd
    
    
    If you have suffered a stroke, have heart disease or have a condition that affects your blood vessels, you may be prescribed a blood thinner such as Xarelto or Pradaxa, known as an anticoagulant. This type of medication is designed to reduce the risk of another stroke or a heart attack by lowering the chances a blood clot will form in a vein or an artery. Blood thinners are also commonly prescribed for patients with congenital heart defects, atrial fibrillation (an abnormal heart rhythm), or those who have undergone heart valve surgery.
29. Xarelto Internal Bleeding Incidents Lawsuit In New Mexico

    Dec 22, 2015 | Blood Thinner Help

    By Joseph Osborne
    
    
    Xarelto is an anticoagulant produced by pharmaceutical companies, Bayer and Johnson & Johnson. This blood thinner has been highly publicized and endorsed by big names like Arnold Palmer and ten-time NBA All-Star Chris Bosh.
30. Xarelto Lawsuit Plaintiffs Point To Studies That Raise Excessive Bleeding Concerns

    Dec 23, 2015 | Mass Tort Nexus

    By Joseph Osborne
    
    
    Two studies have brought new concerns to light regarding blood-thinner Xarelto and dangerous, uncontrollable bleeding episodes. Each study appears to link the anticoagulant to serious and even fatal side effects for patients taking it.
31. Xarelto Bleeding Lawsuit Claims Wrongful Death of Grandmother

    Dec 23, 2015 | Top Class Actions

    By Ashley Vanover
    
    
    Bayer and Johnson & Johnson Pharmaceuticals are facing a wrongful death lawsuit, alleging that their blood thinner Xarelto (also known as rivaroxaban) is dangerous and should not be sold.
32. Xarelto Bleeding Death Lawsuit Filed in Louisiana

    Dec 24, 2015 | Dallas Fort Worth Injury Lawyer

    By Dr. Shezad Malik
    
    
    Ashlie Fluitt from Louisiana, filed a wrongful death claim on behalf of her grandmother who died as a result of catastrophic side effects from using Xarelto. Fluitt alleges that Xarelto anticoagulation medication caused severe brain bleeding which caused her grandmother to die.
33. Xarelto Side Effects & Lawsuit Information

    Dec 24, 2015 | Active Health News

    Xarelto is a blood-thinning drug, or anticoagulant. The U.S. Food and Drug Administration (FDA) approved Xarelto in July 2011, and its sales have steadily grown since then. While bleeding is a common complication associated with anticoagulants, it has been alleged that Xarelto is more dangerous than traditional blood thinners because no antidote exists to reverse its blood-thinning side effects.
34. Judge Stipulates Xarelto Injury Types for Bellwether Trials

    Dec 29, 2015 | Drug Reporter

    By Katarina Siegfeld
    
    
    The presiding judge in the coordinated Xarelto lawsuit proceedings has issued a case management order stipulating the injury categories into which cases must be grouped to be considered for potential bellwether trials, which are expected to take place in 2017 as part of the multidistrict litigation (MDL 2592) created to manage thousands of cases related to the anticoagulant (or blood thinner) alleged to cause serious bleeding problems.
35. Xarelto Lawsuits Show No Sign of Stopping

    Dec 29, 2015 | LawyersandSettlements.com

    By Heidi Turner
    
    
    Xarelto lawsuits alleging patients suffered severe bleeding events after using the anticoagulant drug show no signs of stopping, with 2,400 lawsuits now sitting in the multidistrict litigation for pretrial proceedings. Plaintiffs say they were not warned Xarelto had no antidote and were not warned about the risks of a serious bleeding event while taking Xarelto.
36. Xarelto Stomach Bleed Lawsuit Claims Manufacturers Failed To Recommend Blood Monitoring

    Dec 31, 2015 | AboutLawsuits.com

    By Irvin Jackson
    
    
    A lawsuit recently filed against Bayer Healthcare and Johnson & Johnson’s Janssen subsidiary suggests that individuals nationwide may have been severely injured or died from the bleeding side effects of Xarelto due to the drug makers’ failure to provide adequate warnings about the importance of blood monitoring.
37. Granddaughter Files Xarelto Lawsuit After Her Grandmother Dies of Bleeding

    Dec 31, 2015 | The Legal Examiner

    By Roopal Luhana
    
    
    On November 12, 2015, a Louisiana resident filed a new Xarelto lawsuit in the Eastern District of Louisiana, the current location of the consolidated Xarelto MultiDistrict Litigation (“MDL”).
38. Xarelto Bleeding Lawsuit Filed By Widow

    Jan 1, 2016 | Top Class Actions

    By Robert J. Burns
    
    
    A widow filed a Xarelto lawsuit alleging uncontrolled bleeding caused by the drug cost her husband his life. Plaintiff Carol M. of Roswell, Georgia filed the lawsuit, alleging her husband, Ralph M. died after taking Xarelto.
39. Xarelto Lawsuit: Blood Thinner Caused Life Threatening Bleeding Event

    Jan 4, 2016 | Top Class Actions

    By Robert. J. Burns
    
    
    Another Xarelto lawsuit has joined the ongoing litigation over alleged Xarelto bleeding events. In this Xarelto lawsuit, Plaintiff Edward P. of New Jersey alleges that Xarelto caused life-threatening side effects.
40. Stopping Xarelto Suddenly Could Clot Your Brain

    Jan 4, 2016 | Xarelto Lawsuit Information

    New research shows that patients that stop Xarelto treatment, suddenly are at a high risk of blood clots inside their brain or lungs. A blood clot in the brain can result in paralysis of the body – and can be lethal. Xarelto is a very dangerous medication, mostly because the lack of an antidote makes every single bleeding accident a potential threat to a patient’s life. Xarelto cannot be flushed out from a patient’s body through dialysis, and due to the “once daily” dosage, there’s no way to reduce or adjust the actual dose taken by a patient. What’s worse, however, is that even a mandatory sudden stop in treatment required during a bleeding accident may significantly endanger a patient’s health.
41. Study Suggests Xarelto Presents Greater Risk for Kidney Patients

    Jan 6, 2016 | Drug Reporter

    By Sarah May
    
    
    According to recently-released research findings, next-generation blood-thinning drug Xarelto may pose additional risk to patients who are already suffering from kidney disease. The study, based on data taken from the Department of Defense electronic medical records system, found that those with existing kidney ailments were significantly more likely to experience dangerous internal bleeding while taking the drug than patients without such a condition.
42. Judge For Xarelto Bleeding Lawsuit Claims Advises On Case Selection For Bellweather Trials

    Jan 6, 2016 | Southern Med Law

    The federal judge presiding over Xarelto bleeding lawsuit claims has developed the process for selecting Xarelto cases for discovery and bellwether trials. The federally filed Xarelto bleeding side-effects lawsuits against Bayer HealthCare and Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit, allege that the Xarelto blood thinner causes brain bleeds and internal bleeding episodes that result in hospitalization for transfusion or death. (In Re: Xarelto Products Liability Litigation, No. 2592)

Full Text of Stories Below

Client Attorney Privileged/Attorney Work Product/At Request of Counsel

Plaintiff Attorney Press Releases

1. Xarelto Lawsuit Plaintiffs Look Forward To January Bellwether Case Selection

   Dec 18, 2015 | Blood Thinner Help

   By Joseph Osborne

   BloodThinnerHelp.com reports on announcements that case selection for lawsuits consolidated in Xarelto bleeding lawsuits under multidistrict litigation number 2592 will begin on January 11th of 2016. This litigation is being overseen by the Honorable Judge Eldon Fallon in the Eastern District of Louisiana. Today, they number over 2,200 complaints, all containing similar allegations against Bayer AG and Janssen Pharmaceuticals’ anticoagulant drug, Xarelto.

   While originally thought of as revolutionary, Xarelto has quickly become termed by many as the most dangerous blood thinner currently on the market. This title has primarily been given to the drug due to the fact that it has no available antidote. This simply means that, should a person using Xarelto begin to bleed, physicians will be unable to clot this blood by countering the effects of Xarelto. In these circumstances, if a patient is losing significant blood, doctors must resort to extreme life-saving measures in an attempt to save their life, such as surgery or blood transfusions.

   Traditional blood thinners were released to market with an antidote in vitamin K. When patients taking traditional blood thinners have bleeding episodes, physicians can treat them with vitamin K, countering the effects of the drug and allowing that patient’s blood to clot. This difference can save the patient’s life. Plaintiffs involved in Xarelto lawsuits also allege that the drug actually put them at an increased risk for uncontrollable bleeding, specifically internal bleeding.

   Since the formation of the Xarelto MDL, lawsuit numbers have surged, and they are expected to continue to grow. Presiding Judge Eldon Fallon is currently working on preparing to select  bellwether cases. Initially, he has asked that a 40-case bellwether pool be created. From this pool, 4 bellwether trials will be selected, and these cases will be heard in 2017.

   As this selection process is set to begin in January of 2016, Attorney Joseph Osborne is working to ensure that everyone who has suffered adverse health effects after using Xarelto will have the opportunity to explore their legal rights. These individuals may be entitled to compensation. Attorney Osborne is offering complimentary legal consultations to affected individuals at this time.

   To request additional information on Xarelto lawsuits, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

   http://www.digitaljournal.com/pr/2781920
   

   Return to headline | Return to top

2. Xarelto Lawsuit Multidistrict Litigation Moves Forward Since Establishment 1 Year Ago

   Dec 21, 2015 | Blood Thinner Help

   By Joseph Osborne

   BloodThinnerHelp.com reports today on the recently-increasing numbers of lawsuits filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals. The lawsuits were consolidated one year ago in December of 2014, by the U.S. Judicial Panel for Multidistrict Litigation. This consolidation, which formed multidistrict litigation number 2592, was possible due to the similarities between the over 2,200 lawsuits filed in federal court. Consolidations are done to fast-track the litigation process, helping to avoid different rulings from multiple judges, and duplicate discoveries. Additionally, this consolidation helps those involved to conserve both time and finances.
   

   Since the initial establishment of this MDL, the number of cases filed has grown substantially. Six months after the MDL’s establishment, in June 2015, an estimated 500 lawsuits had been filed.  Court documents show that around just 6 weeks later, however, on July 15th of 2015, the number of filed lawsuits rose to 805. Today, there are over 2,200 lawsuits consolidated in the MDL and these cases are joined by another 500 which have been formed into a mass tort group in Philadelphia, PA. These numbers are expected to continue to increase as time goes on.

   Lawsuits in multidistrict litigation number 2592 are being seen in the United States District Court for the Eastern District of Louisiana. They are located in New Orleans and are being presided over by the Honorable Judge Eldon Fallon. The cases commonly allege that Xarelto can cause dangerous uncontrollable bleeding episodes, which at times prove fatal. Plaintiffs also state that the manufacturer neglected to properly warn consumers of the dangerous side effects associated with the drug, and that through marketing and advertisements, they focused primarily on the positives of the drug.  Finally, lawsuits state that these manufacturers were negligent to release the drug to the market without any corresponding antidote, an extremely dangerous factor for patients who become injured and bleed.

   If a patient using Xarelto becomes injured and starts to bleed, physicians will be unable to counter the effects of the drug and clot their blood. In these instances, doctors have to resort to extreme life-saving measures such as surgeries and blood transfusions in an attempt to save the patient’s life. Patients who take traditional blood thinners do not have these issues. They have an available antidote in vitamin K. If these individuals bleed, unlike with Xarelto, doctors can treat the patient with vitamin K, forcing their blood to clot.

   As these allegations wait to be heard in court, Attorney Joseph Osborne is working to ensure that everyone negatively affected by Xarelto will have the opportunity to explore their legal rights. These individuals could be eligible for compensation. Attorney Osborne is offering free legal consultations regarding Xarelto at this time.

   To ask questions concerning this press release or request additional information, please contact Joseph Osborne at (866) 425-8902.

   http://www.digitaljournal.com/pr/2783616#ixzz3wfiZL5l7
   

   Return to headline | Return to top

3. Xarelto Lawsuit Plaintiffs Note Investigation Of European Regulators Into Xarelto Clinical Trial

   Dec 21, 2015 | Blood Thinner Help

   By Joseph Osborne

   BloodThinnerHelp.com reports on an investigation into Xarelto clinical trials by European regulators. This investigation follows a recent surge in lawsuits filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals commonly alleging that use of the blood-thinner can cause dangerous uncontrollable bleeding events.
   

   The clinical trial that is now under investigation took place at the Duke Institute for Clinical Research. Reports from the Project on Government Oversight indicate that the official who issued the U.S. Food and Drug Administration’s 2011 approval of the drug expressed concerns as well. According to POGO, “The FDA approved Xarelto in 2011 over the objections of the primary FDA scientists assigned to study its safety and effectiveness. The report by the reviewers argued that patients could be ‘at greater risk of harm from stroke and/or bleeding’ if they took Xarelto than if they were treated skillfully with Warfarin, a blood thinner that has been on the market since the 1950’s.”

   POGO additionally notes, “The official who issued the FDA’s decision to approve the drug expressed a series of misgivings about it.” They indicate that this official, FDA Deputy Division Director Stephen M. Grant stated, “The decision was made difficult by the limitations in the design and conduct” of the clinical trial, and that this comment was made in a memo from November of 2011.

   Today, the drug is the subject of more than 2,200 lawsuits filed in federal court in the Eastern District of Louisiana. The cases are being presided over by the Honorable Judge Eldon Fallon, and continue to increase in number. They have been consolidated to form multidistrict litigation number 2592. Xarelto has been given two black box warnings from the FDA, the most serious warnings possible short of fully removing the product from the market.

   The European investigation on Xarelto was also further detailed on AllGov.org, which notes: “The clinical trial relied on blood testing devices that were the subject of two FDA warning letters before the trial began and an FDA recall notice after the trial ended, according to the Project on Government Oversight (POGO). Certain devices in the INRatio product line, the warning notice read, could deliver false test results and that use of those devices may “cause severe or life-threatening injuries, including death.”

   New information shows that the EMA “is currently investigating whether the data generated from the INRatio device could have had any impact on the trial results and the extent of this impact, if applicable.” Additionally, last month, it was reported by POGO that an FDA staff review of the trial indicated that it appeared to be biased in favor of Xarelto approval. As these investigations progress, lawsuits against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals continue to be filed and await trial dates.

   Attorney Joseph Osborne is working to ensure that everyone affected can have the opportunity to evaluate their legal rights. It is believed that those who have taken Xarelto and suffered adverse health events may be entitled to legal action and compensation. Attorney Osborne is offering free legal consultations to involved individuals at this time.

   To learn more, or ask questions, please contact Joseph Osborne, Esq. (866) 425-8902.

   
   http://www.digitaljournal.com/pr/2783748#ixzz3wfjpexa2
   

   Return to headline | Return to top

4. Xarelto Lawsuit Plaintiffs Note Study Linking Drug To Stomach And Eye Bleeding

   Dec 22, 2015 | Blood Thinner Help

   By Joseph Osborne

   BloodThinnerhelp.com reports on studies which appear to point to data bringing up questions surrounding the safety of blood-thinner Xarelto, produced by manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson). The study indicates a potential increase in risk of stomach bleeds and eye-hemorrhaging for patients using the drug.

   The first study, which was done by Doctors John C. Hwang and Judy H. Hun, reported that among patients in their practice in their 70’s and 80’s who had switched from traditional blood thinner Warfarin to new blood thinner Xarelto, more were likely to suffer vitreous hemorrhages. Vitreous hemorrhages are bleeding incidents that occur between the lens of the eye and the retina. These indications, physicians say, were confirmed by testing.

   Further details of the studies note that as the patients began to wean off of blood-thinner Warfarin, and switch over to Xarelto, the bleeds began to occur. These cases were reported to JAMA Ophthalmology and were published in their June, 2015 issue. In their report, doctors Hun and Hwang stated: “In all cases, an acute vitreous hemorrhage occurred shortly after rivaroxaban (Xarelto) treatment was initiated.” The doctors hope that the study results can serve as a warning to physicians switching patients from traditional blood thinners such as Warfarin to Xarelto.

   Another study, which was published in BMJ’s April 2015 issue, found that it was unable to rule out a twofold higher risk of stomach bleeds for individuals taking Xarelto when compared to those taking Warfarin. This study evaluated around 46,000 people to come up with these conclusions. The authors of this study noted that their findings were similar to those of prior studies.

   These studies seem to support the arguments of almost 2,000 lawsuits which have been filed alleging that Xarelto causes dangerous and uncontrollable bleeding in patients. The lawsuits have been consolidated to form multidistrict litigation number 2592 and are being overseen by Judge Eldon Fallon in the Eastern District of Louisiana.

   Attorney Joseph Osborne is working to ensure that everyone who has used Xarelto and has suffered adverse health effects will be able to explore their legal rights. It is still possible for additional cases to join the current Xarelto MDL. Attorney Osborne is offering free legal Xarelto consultations at this time. Those affected may be entitled to compensation.

   To ask questions or request further information on Xarelto lawsuits, contact Attorney Osborne by calling (866) 425-8902.

   http://www.digitaljournal.com/pr/2784701#ixzz3wfiMK7Os
   

   Return to headline | Return to top

5. Xarelto Lawsuit Plaintiffs To Begin Bellwether Trial Selection In Early 2016

   Dec 23, 2015 | Blood Thinner Help

   By Joseph Osborne

   BloodThinnerHelp.com reports on the scheduled case selection for lawsuits consolidated in Xarelto multidistrict litigation number 2592. The selection is currently scheduled to begin in early 2016, specifically on January 11th. Plaintiffs involved are looking forward to seeing things progress. The litigation is being overseen by Judge Eldon Fallon in the Eastern District of Louisiana. Today, Xarelto lawsuits consolidated in the MDL number over 2,200, and all contain similar allegations against Bayer AG and Janssen Pharmaceuticals’ blood thinner.
   

   When it first came on the scene as a brand new type of blood thinner, Xarelto was thought of as revolutionary. It did not require special diets or regular monitoring by physicians as other blood thinners had, and it was the only blood thinner to offer a once-daily, one-size-fits-all dosage for consumers. Shortly after this initial hype wore off, however, consumers began to realize that Xarelto had some downfalls as well. The biggest of which was, perhaps, its lack of available antidote.

   Due to the lack of antidote, patients who were using Xarelto had to be incredibly careful of bleeding injuries. Even a minor injury could result in a dangerous, uncontrollable bleed, because physicians had nothing to treat patients with to reverse the effects of the drug and clot their blood. Today, there is still no available antidote for Xarelo. If someone using the drug is bleeding, doctors have to resort to extreme life-saving measures such as surgery or blood transfusions in an attempt to stop the bleed and clot the patient’s blood.

   Traditional blood thinners have an available antidote in vitamin K. When patients taking these blood thinners become injured and bleed, physicians can treat them with vitamin K, countering the effects of the medication and allowing that patient’s blood to clot. This difference can be a life-saving one.

   Since the formation of the Xarelto MDL, lawsuit numbers have continually surged. Those involved expect that the current number of cases will only continue to grow. Presiding Judge Eldon Fallon has asked that a 40-case bellwether pool be created to help prepare these cases for trial. From this pool, 4 bellwether trials will be selected, and these cases will be heard in 2017. Bellwether trial selection will be based upon which cases seem most trial-ready. This selection process is set to begin in early January of 2016.

   Attorney Joseph Osborne is working to help who has suffered adverse health effects after using Xarelto. He wants to provide these individuals with the opportunity to explore their legal rights. They may be entitled to significant compensation. At this time, Attorney Osborne is offering free legal consultations to those affected.

   To request additional information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

   http://www.digitaljournal.com/pr/2786082#ixzz3wfi6x6OG
   

   Return to headline | Return to top

6. Xarelto Lawsuit Claims Ohio Woman’s Severe Gastrointestinal Bleed Was Caused By The Drug

   Dec 24, 2015 | Blood Thinner Help

   By Joseph Osborne

   BloodThinnerHelp.com reports on a lawsuit filed against the manufacturers Bayer AG and Janssen Pharmaceuicals (a division of Johnson & Johnson), in regard to their blood-thinning drug, Xarelto. The plaintiff claims that the drug caused her severe gastrointestinal bleeding.
   

   The woman, who resides in Ohio, shared further details of her allegations within court documents. The documents note that she was prescribed the drug in order to avoid any blood clots and strokes due to her atrial fibrillation. Atrial fibrillation is a common condition which causes the heart to beat more rapidly than usual, and can put sufferers at increased risk for strokes or blood clots.

   After using Xarelto for less than a year’s time, however, the woman suddenly experienced a severe gastrointestinal bleed, which she believes was caused by the blood thinner. Mounting lawsuits against Xarelto similarly allege that it puts users at increased risk for dangerous and uncontrollable bleeding events.

   Xarelto launched onto the market as a revolutionary new blood thinner after its 2011 approval by the U.S. Food and Drug Association. Unlike other blood thinners released before it, Xarelto did not require users to maintain certain diets or visit their doctors regularly for monitoring. It also provided a one pill per day dosing for everyone, something that no other blood thinner has. These factors originally contributed to the drug’s popularity, however, consumers soon realized that the drug had some drawbacks which had received much less attention.

   Today, many consider Xarelto to be the most dangerous blood thinner on the market. This is mostly due to the fact that the drug offers no available antidote. Plaintiffs allege that manufacturers were negligent to release the drug to the market this way, and note that these manufacturers have yet to provide an antidote.

   Because Xarelto has no antidote, when patients using it begin to bleed, even a tiny injury can turn into a dangerous one. The patients can quickly experience uncontrollable bleeding, and doctors can do nothing to counter the drug and get the patient’s blood to clot. In these cases, doctors have to resort to extreme life-saving measures to attempt to keep the patients alive. They perform surgery or provide blood transfusions.

   Traditional blood thinners do not have these same issues. They have an available antidote in vitamin K, which is why they often require special diets. When a patient using these blood thinners begins to bleed, physicians can administer vitamin K, countering the effects of the blood thinner and allowing the patient’s blood to clot. This antidote can mean the difference between life and death.

   Attorney Joseph Osborne is working to help ensure that anyone who has suffered from an adverse health event after using Xarelto will have the option of exploring their legal rights. Those affected may be entitled to significant compensation. Attorney Osborne is offering complimentary legal consultations for these individuals.

   To obtain more information on Xarelto lawsuits or ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

   
   http://www.digitaljournal.com/pr/2786448#ixzz3wfkB9DNM
   

   Return to headline | Return to top

7. Xarelto Lawsuit Plaintiffs Note Questioning of Trial Results Due To Defective INR Device

   Dec 28, 2015 | Blood Thinner Help

   By Joseph Osborne

    BloodThinnerHelp.com reports on recent news fromReuters which impacts the lawsuits filed against manufacturers of blood-thinner Xarelto. It was learned that both U.S. and European drug regulators have begun to research whether a defective blood-clotting test device may have changed the outcome of certain trial results on the drug.

   Xarelto is currently the subject of over 2,000 lawsuits filed in federal court which similarly allege that it causes dangerous uncontrollable bleeding episodes. The lawsuits surrounding the drug have been consolidated to form multidistrict litigation number 2592 in the Eastern District of Louisiana, and are being overseen by Judge Eldon Fallon. They are accompanied by another group of 500 lawsuits which have formed a mass tort in Philadelphia, Pennsylvania.

   The study reported on was designed to compare Xarelto with a traditional blood thinner called warfarin. It was supposed to evaluate the overall effectiveness of each drug for preventing strokes in patients with atrial fibrillation. Atrial fibrillation is a common heart condition that many patients preventatively take blood thinners to treat. It was reported, however, that during this study, results may have been skewed due to a defect in an International Normalized Ration device used.

   The European Medicines Agency stated: “Due to the defect, it is now thought that the INR device may have impacted the clotting results in some patients in the Warfarin group.” They indicated that results of the study would be published after their investigation into the effects of the defective device had been completed. INR devices are able to measure how quickly blood clots. Unfortunately, the system used for this study was said to have been recalled in December of 2014 when researchers noticed some falsely low results.

   Today, the nearly 2,500 plaintiffs involved in Xarelto lawsuits allege that the blood thinner is the most dangerous one on the market. It has been considered in this light, due to the fact that it was released to the market with no corresponding antidote. This means that if someone using Xarelto becomes injured and bleeds, doctors will not be able to get that person’s blood to clot, and will have to resort to extreme life-saving measures such as blood transfusions or surgeries.

   Individuals taking traditional blood thinners don’t have the same issue, due to the fact that these blood thinners have an antidote in vitamin K. When patients taking traditional blood thinners begin to bleed, doctors are able treat them with vitamin K, which will counter the properties of the drug and allow their blood to clot. This antidote could be the difference between life and death after even what seems like a minor injury.

   As the cases involved in the Xarelto MDL and mass tort group await trial, Attorney Joseph Osborne is hoping to help ensure that everyone who has been negatively affected by Xarelto will have the opportunity to explore their legal rights. Those who took Xarelto and subsequently suffered from adverse health events may be entitled to significant compensation. Attorney Osborne is offering free Xarelto consultations at this time.

   To request additional information regarding the Xarelto lawsuits, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

   http://www.wthr.com/story/30841174/xarelto-lawsuit-plaintiffs-note-questioning-of-trial-results-due-to-defective-inr-device
   

   Return to headline | Return to top

8. Xarelto Lawsuit Alleges Manufacturers Are Liable For Life-Threatening Injuries Caused By Drug

   Dec 28, 2015 | Blood Thinner Help

   By Joseph Osborne

   BloodThinnerHelp.com reports on a lawsuit filed against the manufacturers of blood thinner Xarelto. The suit was filed in the United States District Court for the Southern District of Ohio on October 5th of 2015. It was filed by a husband and wife who are from Morrow County, Ohio.The couple alleges that Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) are responsible for the serious and life-threatening injuries experienced by the wife. Together, they are seeking over $50,000 for medical bills to treat her injuries.
   

   Further details of the complaint explain that the wife was prescribed Xarelto to treat atrial fibrillation, a common heart condition which, in her case, was chronic. The condition puts sufferers at the risk of blood clots and stroke, so blood thinners are frequently used to treat these individuals.

   Xarelto was approved in 2011 by the FDA to treat patients undergoing knee and hip replacement surgeries, shortly after this approval, it was also approved to treat those with atrial fibrillation. Upon its initial release, it was thought of as a revolutionary new type of blood thinner, due to the fact that it did not require special diets or regular check-ins with the physicians as other blood thinners had. Unfortunately, it had some drawbacks as well, that plaintiffs in lawsuits across the nation say they were not made aware of.

   In this particular case, just two months after starting Xarelto, the woman suffered from sudden gastrointestinal bleeding. She alleges that these injuries have required lengthy and costly medical treatments, and that even today, she continues to require medical care due to their effects.

   Lawsuits alleging much the same as this one have seen a recent surge in number. Federal cases number over 2,200 and have been consolidated to form multidistrict litigation number 2592. This consolidation was done by the U.S. JPML due to the fact that cases named similar defendants and discussed similar allegations. The consolidation will help to fast-track the litigation process, avoiding duplicate discovery. It will also help to conserve time and finances for those involved.

   The MDL cases are being overseen by Judge Eldon Fallon in the Eastern District of Louisiana. Additionally, another group of Xarelto lawsuits have been formed in Philadelphia, PA. These cases make up a mass tort group. Plaintiffs involved in all lawsuits share a common allegation: Xarelto can cause dangerous uncontrollable bleeding episodes, and manufacturers were negligent to release the drug to market without a corresponding antidote, and they failed to warn about the severe risks connected to taking the drug.

   Xarelto’s lack of antidote means that if a person using the drug begins to bleed, doctors will be unable to do anything to counter the effects and allow that person’s blood to clot. In these situations, patients require extreme, life-saving measures such as surgeries and blood transfusions. Traditional blood thinners, however, offer an available antidote in vitamin K. If a person taking a traditional blood thinner begins to bleed, physicians can treat them with vitamin K, which will allow their blood to clot. The availability of antidote in this case can mean the difference between life and death.

   Attorney Joseph Osborne is currently working to ensure that everyone who has been negatively affected by Xarelto will have the opportunity to explore their legal rights. Those who have used Xarelto and have subsequently experienced adverse health effects may be entitled to compensation. Attorney Osborne is offering free legal consultations to those involved at this time.

   To ask questions or request additional information about Xarelto lawsuits, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

    http://www.digitaljournal.com/pr/2787392#ixzz3wfqHB2fZ
   

   Return to headline | Return to top

9. Xarelto Lawsuit Alleges Texas Woman’s Life-Threatening Internal Bleed Caused By Drug

   Dec 28, 2015 | Blood Thinner Help

   By Joseph Osborne

   BloodThinnerHelp.com reports on the details of a lawsuit which was filed in the Eastern District of New York by a woman from Texas. The woman alleges that Xarelto manufacturers Janssen Pharmaceuticals, (a division of Johnson & Johnson), and Bayer AG failed to adequately warn consumers about the dangers associated with their blood thinning drug. Her complaint was filed in a federal court under number 1:14-cv-04524, but was later transferred, as Xarelto cases were consolidated to form multidistrict litigation number 2592 in Louisiana.
   

   Details of the suit indicate that the plaintiff was prescribed Xarelto to treat her atrial fibrillation. This is a heart condition that can cause strokes and blood clots. As a preventative measure, people with this condition are commonly prescribed blood thinners. In this specific case, the plaintiff began to take Xarelto just 5 months prior to suffering a life-threatening internal bleed which, she claims, has now left her in need of long-term medical care.

   Xarelto was approved by the U.S. Food and Drug Administration in 2011. It was initially well-received, as it did not require regular monitoring or adjustments by physicians as all other blood thinners did, and consumers did not have to maintain a specific diet while taking it.

   The excitement over this new type of anticoagulant was short lived, however, as certain consumers realized that it had been released to the market without a corresponding antidote. Suddenly, many considered the drug to be the most dangerous blood thinner available. Today, over four years after its initial launch, manufacturers have yet to release an antidote for the drug.

   The lack of antidote means that if a patient with Xarelto in their system becomes injured and bleeds, physicians may not be able to counter the drug’s effects and clot their blood. In these instances, physicians must resort to extreme life-saving measures, such as blood transfusions or surgeries in an attempt to keep the patient alive. If the blood pools in the brain or other areas and develops pressure, surgery will be necessary.

   Patients taking traditional blood thinners do not have this issue, because these blood thinners have an available antidote in vitamin K. When a patient using a traditional blood thinner becomes injured and bleeds, physicians have the option of treating them with vitamin K to counteract the effects of the drug and allow their blood to clot. This can make a tremendous difference when a patient is losing lots of blood; one that could save their life.

   Today, Xarelto lawsuits which synonymously allege that the drug can cause increased risk for dangerous and uncontrollable bleeding episodes number around 2,200 cases in federal court. They are joined by another 500 cases which have been consolidated to form a mass tort group in Philadelphia, Pennsylvania.

   Attorney Joseph Osborne is currently working to ensure that everyone affected by Xarelto can have the opportunity to evaluate their legal rights. Patients who used the blood thinner and later suffered adverse health effects could be entitled to significant compensation. Attorney Osborne is offering complimentary legal consultations to involved parties at this time.

   To ask questions, or request additional information on Xarelto bleeding lawsuits, contact Attorney Joseph Osborne by calling (866) 425-8902.

   http://www.digitaljournal.com/pr/2787137#ixzz3wgBe2P4c
   

   Return to headline | Return to top

10. Xarelto Lawsuit Increase Reported In Philadelphia Court Of Common Pleas

    Dec 29, 2015 | Blood Thinner Help

    By Joseph Osborne

    
    

    BloodThinnerHelp.com reports on the steady increase of lawsuits filed against Bayer AG and Janssen Pharmaceuticals in connection with their blood thinning drug Xarelto. Today, lawsuits filed in the Philadelphia Court of Common Pleas in Pennsylvania number around 500 cases. This number has dramatically risen since September, when a reported 300 cases were involved. Additionally, cases filed against the drug in federal court have been consolidated to form multidistrict litigation number 2592 by the U.S. Judicial Panel on Multidistrict Litigation.

    MDL number 2592 is located in the Eastern District of Louisiana and is being overseen by Judge Eldon Fallon. The cases consolidated in this MDL now number 2,200, and have also steadily increased since the original consolidation.

    Janssen Pharmaceuticals, one of the defendants named in the lawsuit, is a subsidiary of pharmaceutical giant Johnson & Johnson. Lawsuits against Janssen and Bayer AG similarly state that blood thinner Xarelto can cause dangerous and serious health problems, specifically uncontrollable bleeding which can quickly turn fatal. Due to the fact that Xarelto was released to the market without an antidote, medical professionals have noted that when someone taking the drug suffers an injury and begins to bleed, there is little that can be done to stop them from losing too much blood. In these instances, physicians have to resort to extreme, life-saving measures such as surgeries and blood transfusions.

    Traditional blood thinners offer an antidote in vitamin K, so when patients using these blood thinners are bleeding, doctors are able to treat them with vitamin K to clot their blood and potentially save their life.

    As these Xarelto lawsuits await trial the number of cases involved in the mass tort group and the MDL are expected to steadily continue to increase. Attorney Joseph Osborne is working to ensure, in the meantime, that everyone who has used Xarelto and suffered medical problems, that they attribute to the drug, will have the opportunity to explore their legal rights. Attorney Osborne is offering complimentary legal consultations for everyone affected at this time. Those who have suffered due to the drug may be entitled to significant compensation.

    To request additional information on Xarelto bleeding lawsuits, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

    http://www.digitaljournal.com/pr/2788064
    

    Return to headline | Return to top

11. Xarelto Lawsuit Plaintiffs Blame Drug For The Death Of Their Family Members

    Dec 29, 2015 | Blood Thinner Help

    By Joseph Osborne

    BloodThinnerHelp.com reports on a lawsuit filed by a group of 10 residents from multiple states who are similarly suing pharmaceutical manufacturers, allegeing that blood thinner Xarelto has caused their family members some very dangerous and even fatal side effects.

    The plaintiffs are made up of a group of special administrators for family members who have passed away allegedly because of using Xarelto. The lawsuits were filed together on November 20th of 2015 in a St. Clair County Circuit Court under number 15-L-670. Defendants named are Bayer AG and Janssen Pharmaceuticals, (a subdivision of Johnson & Johnson), among others.

    Details of the complaint state that defendants have been involved in the research, design, development, and distribution of Xarelto, and have all presented the drug as a safe and effective treatment for patients undergoing knee and hip replacement surgeries. The suit says that through marketing and advertisements of the drug, it was falsely presented. Additionally, they state that the efficacy of the drug was oversold.

    It is noted that defendants received a letter from the U.S. Food and Drug Administration on June 6th of 2013 which alleged that their claims were misleading, and primarily focused on new, positive aspects of the blood thinner. Additionally, the complaint alleges that Xarelto manufacturers were negligent in releasing the drug to the market without any corresponding antidote.

    Having no corresponding antidote means that when a patient with Xarelto in their system becomes injured and bleeds, physicians will be unable to clot their blood and stop that bleed. Often, in these situations, physicians have to resort to extreme, life-saving measures such as blood transfusions or surgery.

    Patients who use traditional blood thinners alternatively have an available antidote in vitamin K. When these patients become injured and bleed, physicians can administer vitamin K, counteracting the effects of the drug and clotting their blood. This can be a lifesaving difference.

    The lawsuit goes on to charge a total of nine defendants with strict product liability, negligence and negligent misrepresentation, fraud, and wrongful death. Plaintiffs involved are seeking a minimum of $50,000 for each deceased family member, as well as money to cover legal fees.

    Attorney Joseph Osborne is working to ensure that anyone else who may have taken Xarelto and suffered adverse health effects will have the opportunity to investigate their legal options. These individuals may be entitled to compensation. Attorney Osborne is offering free legal consultations for those involved.

    To ask questions or request more information, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

    https://www.pressadvantage.com/story/6758-xarelto-lawsuit-plaintiffs-blame-drug-for-the-death-of-their-family-members
    

    Return to headline | Return to top

12. Xarelto Lawsuit Plaintiffs Look Forward To Upcoming Bellwether Trials

    Dec 29, 2015 | Blood Thinner Help

    By Joseph Osborne

    BloodThinnerHelp.com reports on the announcement of Bellwether trial dates for the Xarelto multidistrict litigation number 2592. The consolidated cases will be overseen in the Eastern District of Louisiana by the Honorable Judge Eldon Fallon. Recently released court documents indicate that the first two bellwether trials are scheduled to be heard on February 6th, 2017 and March 13th of 2017, and the final two bellwether trials are scheduled to be heard on April 24th and May 30th of 2017. As 2016 approaches, plaintiffs prepare for bellwether selection from a pool of 40 cases. Those involved look forward to seeing things continue to progress.
    

    Recently, federally filed Xarelto lawsuits have surged, with over 2,200 now involved in the MDL. These cases are additionally joined by another 500 which have been consolidated to form a mass tort group in Philadelphia, Pennsylvania. The complaints in these cases similarly allege that use of Xarelto poses an increased risk for uncontrollable bleeding.

    Xarelto has been linked to health problems including gastrointestinal bleeding, strokes, blood clots, and brain hemorrhages. Other plaintiff allegations state that manufacturers Bayer AG and Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) failed to properly warn consumers about all of the dangers associated with the drug. Instead, they allege, manufacturers focused their advertisements on the benefits of the ‘revolutionary’ new type of anticoagulant.

    Xarelto has been the subject of much recent controversy and been termed ‘the most dangerous blood thinner currently on the market’ by many. This new title has been earned due to the fact that the drug was released to the public without any corresponding antidote, and, even today, the manufacturers have yet to release an antidote for the blood-thinner.

    No antidote is a dangerous thing. It means that when someone who has taken Xarelto begins to bleed, their blood is unable to clot. In these circumstances, physicians must resort to life saving measures, by giving blood transfusions or performing surgery. When patients taking traditional blood thinners begin to bleed, physicians have an available antidote in vitamin K. They can administer vitamin K which will counteract the effects of the drug and allow the patient’s blood to clot. The available antidote, in many cases, can be the difference between life and death.

    Attorney Joseph Osborne is working to help anyone who has taken Xarelto and has suffered adverse health effects that they attribute to the drug, so that they will be able to explore their full legal rights. These people may be entitled to legal action and compensation. Attorney Osborne offers free legal consultations to those affected at this time.

    To request more information on Xarelto lawsuits, or to ask questions, contact Joseph Osborne, Esq. by calling 866-425-8902.

    
    http://www.digitaljournal.com/pr/2787973#ixzz3wgC3hOkv
    

    Return to headline | Return to top

13. Xarelto Lawsuit Plaintiffs Note Dangerous Risk Of No Antidote For Blood Thinner

    Dec 30, 2015 | Blood Thinner Help

    By Joseph Osborne

    BloodThinnerHelp.com reports on a fact that has come up frequently in the ever-increasing number of lawsuits filed against manufacturers of Xarelto: the lack of antidote available for the drug. Plaintiffs allege that this is an example of extreme negligence on the part of manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of pharmaceutical giant Johnson & Johnson); one that can cause dangerous and even fatal problems to occur in patients.
    

    The Xarelto bleeding lawsuits are just a bit over a week away from bellwether trial selection, and continue to increase in number. The complaints have been consolidated in the Eastern District of Louisiana under multidistrict litigation number 2592, and are being overseen by Judge Eldon Fallon. The consolidation was approved by the U.S. Judicial Panel on Multidistrict Litigation due to the fact that cases were filed against the same defendants and contained synonymous allegations.

    Plaintiffs involved in the lawsuits consider the lack of antidote to be incredibly dangerous. When someone using Xarelto suffers even minor injuries that cause bleeding, doctors will not be able to get their blood to clot due to the anticoagulant. In these situations, the doctors must resort to extreme, life-saving tactics such as surgery or blood transfusions. If the blood has pooled in an area such as the brain, surgery will be necessary to relieve pressure and attempt to save the person’s life.

    More traditional blood thinners do not have this issue. They offer an antidote in vitamin K. When patients using traditional blood thinners are injured and bleeding, they are treated with vitamin K to reverse the blood thinner’s effects and clot their blood. The antidote can mean the difference between life and death for many people.

    Initially, in 2011, Xarelto was released to the market and approved by the FDA. It was intended to help prevent deep vein thrombosis for patients undergoing knee or hip replacement surgeries. Several months later, the drug also gained approval to treat patients suffering from atrial fibrillation, a common heart condition which can cause strokes or blood clots.

    Today, Xarelto has become widely considered one of the most dangerous blood thinners available, and is the topic of over 2,200 federal lawsuits consolidated in a federal court.

    As the Xarelto lawsuits await trial, Attorney Joseph Osborne is attempting to ensure that everyone affected by the drug will have the opportunity to evaluate their legal rights. Those who suffered adverse health effects after using Xarelto may be entitled to compensation. Attorney Osborne is offering free legal consultations for affected individuals.

    To ask questions or request more information on Xarelto lawsuits, contact Joseph Osborne, Esq. by calling (866) 425-8902.

    http://www.digitaljournal.com/pr/2788444#ixzz3wgFwVaf9
    

    Return to headline | Return to top

14. Xarelto Lawsuit Plaintiffs Claim Blood Thinner Advertisements Are Misleading

    Dec 31, 2015 | Blood Thinner Help

    By Joseph Osborne

    BloodThinnerHelp.com reports on recent advertisements for blood thinning drug Xarelto, manufacturered by Bayer AG and Janssen Pharmaceuticals, (a division of Johnson & Johnson). Although the anticoagulant is the subject of over 2,800 lawsuits in federal court multidistrict litigation, these advertisements seem as prevalent and persistent as ever.

    Recent ads feature the endorsements of popular celebrities, including Brian Vickers (a popular NASCAR driver), Kevin Nealon (an SNL alumni), Chris Bosh (a popular NBA player), and Arnold Palmer (a golf legend). During the commercials, each celebrity discusses their experiences with the blood thinner, which, of course, are all positive. Among the topics discussed by the celebrities, are Xarelto’s effectiveness at reducing the risk of blood clots, pulmonary embolism, strokes, and deep vein thrombosis.

    Plaintiffs involved in the continuously growing number of lawsuits, however, have a very different perspective. They are focused on the significant dangers of uncontrollable bleeding they associate with the drug, specifically internal bleeds, as well as the drug’s lack of antidote, which can cause even a minor bleeding injury to become potentially fatal.

    Xarelto’s lack of antidote means that if someone using the drug begins to bleed, doctors will be unable to clot their blood and stop that bleed. In these instances, doctors must resort to extreme, life-saving medical treatments such as blood transfusions or surgery to stop pooling blood.

    Traditional blood thinners, such as warfarin, do not have the same issue as they do, in fact, they offer an antidote for consumers. When individuals using traditional blood thinners begin to bleed, physicians can treat them with vitamin K, which will counter the effects of the drug and allow the patient’s blood to clot.

    Because of its sensitivity to vitamin K, warfarin requires that users follow a specific diet. In Xarelto advertisements, the celebrities note this fact as a drawback. They neglect to mention why it requires a special diet, however, which is due to the fact that the drug offers an antidote; a potentially life-saving characteristic.

    The 2,800 Xarelto lawsuits reportedly now involved in MDL number 2592 are being overseen in the Eastern District of Louisiana by the Honorable Judge Eldon Fallon. As the cases await trial, others will be able to join them, which is why Attorney Joseph Osborne is currently working to ensure that everyone negatively affected by the drug will have the opportunity to investigate their legal rights. Attorney Osborne is offering free Xarelto consultations at this time.

    To ask questions or request additional information concerning Xarelto uncontrollable bleeding lawsuits, contact Joseph Osborne, Esq. by calling (866) 425-8902.

    http://www.digitaljournal.com/pr/2789514#ixzz3wgFYOawv
    

    Return to headline | Return to top

15. Xarelto Lawsuit Plaintiff Blames Negligence Of Blood Thinner Manufacturers For Husband’s Death

    Jan 4, 2016 | Blood Thinner Help

    By Joseph Osborne

    BloodThinnerHelp.com reports on a lawsuit filed which highlights the dangerous side effects connected to anticoagulant Xarelto. This lawsuit, joined with many others, is consolidated in multidistrict litigation number 2592 by the U.S. Judicial Panel on Multidistrict Litigation. The MDL, created to help simplify and fast-track the litigation, is being overseen by the Honorable Judge Eldon Fallon in the Eastern District of Louisiana.

    This particular complaint was filed by a widow from Missouri who alleges that the negligence of Bayer Healthcare and Janssen Research, (a subdivision of Johnson & Johnson), ultimately caused her husband’s death.

    Details within the court documents indicate that the woman’s husband was prescribed Xarelto in December of 2012 by his doctor. He took the drug up until he was admitted to an intensive care unit on May 4th of 2013 due to an intracerebral hemorrhage or brain bleed. Hospital staff attempted to save his life, but were unable to stop the fatal bleed due to the blood thinning drug which was still in his system.

    As many others who have filed their own lawsuits against Xarelto say, the plaintiff states that if she and her husband had been made aware of the dangers associated with the drug, they would never have used it. Additionally, she states that the defendants failed to properly warn consumers or doctors about the dangers of Xarelto’s side effects, and may have even purposefully concealed information regarding the drug’s risks from the public, so as not to decrease their profits.

    Across the U.S., Xarelto lawsuits continue increase in number. In federal court, they now number over 2,200, and are joined by another mass tort group in Philadelphia, Pennsylvania of around 500 cases. Plaintiffs involved share similar allegations about the blood thinner, which commonly note its lack of antidote and uncontrollable bleeding risks.

    Attorney Joseph Osborne is working to ensure that as these cases await trial, everyone who has experienced adverse health effects after using Xarelto will have the option of fully exploring their legal rights. In order to accomplish this, he is currently offering complimentary legal consultations to those involved. It is believed that these people may be entitled to substantial compensation.

    To ask questions or request additional information, please contact Attorney Osborne by calling (866) 425-8902.

    http://www.digitaljournal.com/pr/2790672#ixzz3wgCKZ6OE
    

    Return to headline | Return to top

16. Philadelphia Court Of Common Pleas Reports Xarelto Lawsuit Increase In Mass Tort Group

    Jan 6, 2016 | Blood Thinner Help

    By Joseph Osborne

     BloodThinnerHelp.com reports on the continued increase of lawsuits filed against Bayer AG and Janssen Pharmaceuticals which discuss the blood thinner they manufacture: Xarelto. Today, lawsuits filed in the Philadelphia Court of Common Pleas in Pennsylvania have reportedly surpassed 500 cases. This number has significantly grown since September of 2015, at which point a reported 300 cases had been filed.

    These Philadelphia cases are also joined by a group of cases filed against Xarelto manufacturers in federal court which have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form multidistrict litigation number 2592. The MDL is located in the Eastern District of Louisiana and is being overseen by the Honorable Judge Eldon Fallon. This grouping includes over 2,800 cases according to plaintiffs, and this number continues to grow as well.

    Janssen Pharmaceuticals, a defendant named in the lawsuit groups, is a subsidiary of pharmaceutical conglomerate Johnson & Johnson. Lawsuits against Janssen and Bayer AG synonymously allege that anticoagulant Xarelto can cause dangerous and serious uncontrollable bleeding episodes which can quickly escalate and turn fatal.

    Xarelto was released to the market by its manufacturers without any antidote. For this reason, medical professionals have noted that when someone with the drug in their system suffers even a minor injury and begins to bleed, there is little that can be done to stop them from losing excessive blood. In these circumstances, physicians must resort to extreme, life-saving measures such as surgeries or blood transfusions.

    Traditional blood thinners, such as warfarin, do not pose this issue to those using them. These medications offer an antidote through vitamin K. When patients using them are injured and begin to bleed, doctors are able to treat them with vitamin K which counteracts the medication’s blood thinning effects and clots their blood. This antidote could easily be the difference between life and death in emergency situations. Plaintiffs in Xarelto lawsuits say that defendants were downright negligent and reckless by releasing their blood thinner to market without such an important counterpart.

    As all of the Xarelto lawsuits await trial, Attorney Joseph Osborne is working to offer legal aid to everyone who has used Xarelto and suffered medical problems that they attribute to the drug. These consumers deserve the opportunity to fully explore their legal rights. Attorney Osborne is offering free Xarelto consultations for everyone affected at this time. Those who have suffered after using the drug may be entitled to legal action and compensation.

    To ask questions or request additional information on Xarelto bleeding lawsuits, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

    http://www.nbcrightnow.com/story/30901563/philadelphia-court-of-common-pleas-reports-xarelto-lawsuit-increase-in-mass-tort-group
    

    Return to headline | Return to top

17. British Medical Journal Xarelto Study Cited In Arguments Of Xarelto Lawsuit Plaintiffs

    Jan 6, 2016 | Blood Thinner Help

    By Joseph Osborne

    BloodThinnerHelp.com reports on studies surrounding blood thinner Xarelto. Xarelto is an anticoagulant which launched in the U.S. market with initial tremendous success. The U.S. Food and Drug Association approved the drug in 2011, intending it to reduce the risk of strokes and blood clots for patients healing from hip or knee replacement surgeries. After its initial approval, Xarelto was also expanded to treat deep vein thrombosis and pulmonary embolism, and was also used preventatively to treat patients with atrial fibrillation.

    An aggressive marketing campaign which launched with the revolutionary new type of blood thinner put much focus on its differences from older blood thinner medications. Unlike traditional blood thinners, Xarelto did not require regular monitoring by physicians, or special diets, and it was the only blood thinner on the market to offer a one-size-fits-all, once daily dosage.

    Over the years, however, public perception of the drug quickly changed. Today, the almost 3,000 plaintiffs who have stepped forward to file suit against manufacturers of the drug call Xarelto the most dangerous blood thinner currently on the market. They commonly allege that the drug puts users at increased risk for severe, uncontrollable bleeding episodes, some of which have proven fatal.

    A study published in the British Medical Journal seemed to support the arguments of the plaintiffs, highlighting a potential twofold increased risk for episodes of gastrointestinal bleeding for patients using Xarelto as opposed to the generic form of traditional blood thinner warfarin.

    The study observed nearly 50,000 patients, and was designed to determine the overall effectiveness and safety of rivaroxaban (which is the generic form of Xarelto). It compared risks associated with the blood thinner to risks associated with those of warfarin. Researchers concluded that they could not “…rule out a more than twofold higher risk of bleeding with rivaroxaban compared with warfarin.”

    Federally filed lawsuits have been consolidated to form a multidistrict litigation in a single courtroom. As the cases await trial, Attorney Joseph Osborne has been busy attempting to ensure that everyone negatively affected by the drug will have the opportunity to explore their legal rights. He believe that individuals who used Xarelto and suffered from severe health complications that they attribute to the drug may be entitled to legal action and significant compensation. At this time, Attorney Osborne is offering complimentary legal consultations for involved parties.

    To request additional information or ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

    http://www.kswo.com/story/30901307/british-medical-journal-xarelto-study-cited-in-arguments-of-xarelto-lawsuit-plaintiffs
    

    Return to headline | Return to top

18. Xarelto Lawsuit Alleges Drug Caused Georgia Man's Internal Bleeding Death

    Jan 6, 2016 | Blood Thinner Help

    By Joseph Osborne

    BloodThinnerHelp.com reports on a lawsuit now joining the over 2,800 cases federally filed in the Xarelto MDL. This particular case was filed in the Eastern District of Louisiana under complaint number 2:15-cv-00885. It was filed for a Georgia man who had passed away by his son. Allegedly, the man had died due to internal bleeding caused by Xarelto, so the son filed suit against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson).

    Outside of the nearly 3,000 cases filed in federal court against Xarelto, there is also a Mass Tort Group of around 500 cases which has formed in Philadelphia, Pennsylvania. Both of these consolidations are formed in order to fast track the legal process, avoiding duplicate discovery or different rulings from multiple judges, and conserving resources of those involved.

    Documentation indicates that this complaint was filed on March 20th of 2015, and details show that the son says blood thinner Xarelto caused his father’s fatal uncontrollable bleeding episode. The father had been prescribed Xarelto to treat his atrial fibrillation condition, a common heart condition which can cause strokes and blood clots. The plaintiff states that he and his family were unaware of the serious dangers of Xarelto, specifically the fact that it has no available antidote. Had they known this information, he insists, they would have chosen an alternative anticoagulant.

    Due to the recent surge in lawsuits against the drug, Xarelto has now become what many refer to as the most dangerous blood thinner on the market. Many are angry that it was released to the market with no antidote, and that manufacturers have yet to develop one, four years later.

    Without an available antidote, if a patient using Xarelto is injured and bleeds, physicians will not be able to stop their bleeding or clot their blood. In these instances, physicians have to resort to extreme emergency, life-saving treatments such as surgery or blood transfusions. Traditional blood thinners are a different story in that have an antidote in vitamin K. If a patient using a traditional blood thinner is bleeding, doctors treat them with vitamin K to counteract the medicine’s effects and clot their blood.

    Attorney Joseph Osborne is currently working to ensure that anyone who has taken Xarelto and has suffered from adverse health events will have the opportunity to fully explore their legal rights. These individuals may be entitled to legal action and compensation. Attorney Osborne is offering complimentary Xarelto consultations at this time.

    To obtain more information or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

    http://www.wlox.com/story/30890987/xarelto-lawsuit-alleges-drug-caused-georgia-mans-internal-bleeding-death
    

    Return to headline | Return to top

19. Xarelto Lawsuit Alleges Blood Thinner Caused Severe Gastrointestinal Bleed For Ohio Woman

    Jan 6, 2016 | Blood Thinner Help

    By Joseph Osborne

    BloodThinnerHelp.com reports on another lawsuit which was filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson). The plaintiff involved claims that the blood thinning drug caused her dangerous and severe gastrointestinal bleed, which has left her with long-term medical needs.

    The woman, who is a resident of Ohio, expanded on the details of her allegations within her court documents. The documents indicate that she was prescribed Xarelto by her family doctor in order to treat her atrial fibrillation. This is a fairly common heart condition which can cause blood clots or strokes.

    Unfortunately for the plaintiff, she claims that she suddenly experienced a severe gastrointestinal bleed while taking Xarelto. At the time, she had taken the drug less than one year. Xarelto has been linked to dangerous uncontrollable bleeding episodes, specifically internal ones, by many people across the United States.

    Xarelto was approved by the U.S. Food and Drug Association in 2011. It was initially intended to treat patients who had undergone knee or hip replacement surgeries or who had deep vein thrombosis, and to help prevent strokes and blood clots. Shortly after its approval, its approved use was expanded to include treatment for atrial fibrillation.

    Although Xarelto had benefits such as once-daily dosage and no need for regular monitoring by physicians or special diets, it had one major drawback: a complete lack of corresponding antidote. Plaintiffs call Xarelto’s release to market without an antidote both negligent and dangerous.

    Without an antidote, when patients with Xarelto in their system begin to bleed, even a minor injury can turn into a dangerous or even fatal one. Patients who are bleeding can rapidly experience uncontrollable bleeding, and doctors will be unable to do anything to get the patient’s blood to clot. In these situations, doctors must resort to extreme life-saving measures. They generally have to perform surgery to relieve pressure from pooling blood, or provide blood transfusions to prevent bleed outs.

    Patients using traditional blood thinners, such as warfarin, are better able to avoid these issues. Traditional blood thinners have a corresponding antidote through vitamin K, which is why patients using these blood thinners often require special diets. When a patient taking a traditional blood thinner begins to bleed, physicians administer vitamin K to counteract the effects of the medication and allow the patient’s blood to clot more quickly and easily. This antidote can easily mean the difference between life and death.

    Attorney Joseph Osborne is working to ensure that anyone who has suffered from an adverse health event after using Xarelto can have the option of exploring their legal rights. Those affected may be entitled to legal action and compensation. Attorney Osborne currently offers complimentary legal consultations for those affected.

    To obtain additional information concerning Xarelto, or ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

     http://www.digitaljournal.com/pr/2794388#ixzz3wgDsrtoH
    

    Return to headline | Return to top

20. Xarelto Lawsuit Plaintiffs Note JAMA Ophthalmology Studies Linking Drug To Dangerous Bleeds

    Jan 8, 2016 | Blood Thinner Help

    By Joseph Osborne

     BloodThinnerhelp.com reports on several studies which point to data that brings up questions surrounding the safety of blood thinning drug Xarelto. The anticoagulant is produced by manufacturers Bayer AG and Janssen Pharmaceuticals (a division of pharmaceutical giant Johnson & Johnson). The studies indicate a link to dangerous bleeding, including stomach bleeds and eye-hemorrhaging episodes to those who use Xarelto.

    The initial study, completed by Doctors John C. Hwang and Judy H. Hun after reviewing patients in their practice, reported that patients ages 70-89 who had previously used traditional blood thinner Warfarin but had later switched to use new blood thinner Xarelto, were at a greater risk of suffering from vitreous hemorrhages. These are bleeding incidents which occur between the lens and retina of the eye. Testing confirmed that patients who had switched blood thinners were at an increased risk of this occurrence.

    Further study details indicate that as the evaluated patients began to wean off of their traditional blood thinner (Warfarin), and switch over to Xarelto, this is when the bleeding incidences would occur. These cases were published in JAMA Ophthalmology’s June, 2015 issue. The overseeing doctors stated within their reports that: “In all cases, an acute vitreous hemorrhage occurred shortly after rivaroxaban (Xarelto) treatment was initiated.” The doctors hope that their findings will dissuade patients currently on traditional blood thinners from switching to Xarelto and putting themselves at risk.

    An additional study, published in BMJ’s April 2015 issue, noted that researchers could not rule out out a twofold increased risk of stomach bleeding for patients taking Xarelto in comparison to those using Warfarin. This study observed nearly 46,000 people in order to come to this conclusion.

    These studies appear to support the arguments of almost 2,800 plaintiffs who have filed lawsuits alleging that Xarelto caused dangerous and uncontrollable bleeding, which, in some cases, proved fatal. Plaintiffs look to these study results to help illustrate their arguments about the significant dangers of the drug. Their lawsuits have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL number 2592. They are being overseen by the Honorable Judge Eldon Fallon in the Eastern District of Louisiana.

    As these cases await trial, Attorney Joseph Osborne is working to ensure that everyone who has used Xarelto and who has since suffered from adverse health events will have the opportunity to explore their legal rights. It is possible for additional cases to join the current MDL at this time. Attorney Osborne is currently offering free Xarelto consultations. Those affected may be entitled to legal action and significant compensation.

    To ask questions or request additional information on Xarelto lawsuits, contact Attorney Osborne by calling (866) 425-8902.

    http://www.cbs19.tv/story/30889683/xarelto-lawsuit-plaintiffs-note-jama-ophthalmology-studies-linking-drug-to-dangerous-bleeds
    

    Return to headline | Return to top

Plaintiff Attorney Blog Posts

21. FDA Approval of Xarelto May Have Been Based on False Data

    Dec 18, 2015 | Drug Reporter

    By Dawn Snyder

    Thousands of Xarelto users have brought federal lawsuits against the drug’s manufacturers alleging that the anticoagulant causeduncontrollable bleeding and severe injuries.

    Recent reports shed light on a how the drug made it to the market with FDA approval. The anticoagulant’s drug trial was based on what may have been a faulty measurement device, potentially skewing the results.About Xarelto

    Xarelto, manufactured by Johnson & Johnson and Bayer Healthcare, is one of a newer generation of anticoagulants that was released as a head-to-head competitor to warfarin. Approved by the FDA more than half a century ago, warfarin had been the leading anticoagulant but requires close monitoring; a doctor is required to personalize dosing according to factors like a patient’s age and diet.

    Xarelto, and similar drugs that include Pradaxa and Eliquis, promised to be a safer alternative that make a doctor’s continual monitoring of the patient unnecessary. But an inherent risk in using a blood thinner is excessive bleeding, and bleeding events with warfarin are easier to control. Warfarin works by slowing vitamin K production and bleeding can be reversed by administering a dose of vitamin K.

    Xarelto works in a different fashion and there is no known antidote for the bleeding events they cause.

    Trials incorporated recalled device

    The FDA approved Xarelto in 2011 to reduce the risk of deep vein thrombosis and pulmonary embolism. Approval was based in part on Xarelto’s clinical trials, known as ROCKET-AF, which compared the rate of blood clotting between Xarelto and warfarin.

    A device called INRatio, by Alere, was a crucial piece in the trials; INRatio measured the level of warfarin in a test subject’s blood and adjusted the dosage. But the device was recalled in December 2014 because some units were reporting readings that were artificially low. The malfunction could have had a significant effect on the Xarelto trial; readings that were misreported too low would have resulted in patients on warfarin receiving an excessive does, increasing the chances that they would experience a bleeding event and creating the false impression that Xarelto had a comparatively lower rate of internal bleeding.

    The chances that an INRatio malfunction affected the study are good – Alere has received reports ofnearly 19,000 malfunctions, with 14 citing serious injuries. Records indicate that the FDA had issued warning letters about INRatio devices before the trial began in 2006.

    Widespread impact of Xarelto

    Following a growing trend, Xarelto has been heavily marketed directly to consumers with commercials featuring professional actors and athletes. It reached $1.5 billion in U.S. sales last year, having been prescribed to more than 3 million American patients.

    Nearly 19,000 people have filed Xarelto lawsuits in federal courts over injuries allegedly caused by excessive bleeding events while taking the medication. The federal cases have been consolidated for pretrial purposes in multidistrict litigation proceeding. The first cases from the proceeding are expected to go to trial in mid-late 2016 and their outcomes will likely set the tone for possible negotiations for the thousands of remaining cases.

    http://drugreporter.com/2015/12/fda-approval-xarelto-have-been-based-false-data/
    

    Return to headline | Return to top

22. Xarelto Bleeding Lawsuits in MDL Hit 2,400

    Dec 18, 2015 | AboutLawsuits.com

    By Irvin Jackson

    According to a recent case list released by the U.S. Judicial Panel on Multidistrict Litigation (JPML), there are currently at least 2,400 Xarelto lawsuits pending throughout the federal court system, which all involve similar allegations that users of the controversial anticoagulant suffered uncontrollable bleeding or other problems.

    Since December 2014, the Xarelto litigation pending throughout the federal court system has been consolidated for pretrial proceedings as part of an MDL, or multidistrict litigation.

    Complaints filed nationwide are centralized before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana to reduce duplicative discovery into common issues in the cases, avoid contradictory pretrial rulings from different judges and to serve the convenience of the parties, witnesses and the courts.

    One year after the Xarelto MDL was established, the U.S. JPML reports (PDF) that the number of cases transferred from U.S. District Courts nationwide continues to climb, with many of the cases involving multiple plaintiffs who suffered bleeding injuries.

    Thousands of Xarelto Bleeding Problems

    Xarelto (rivaroxoaban) was introduced in 2011 as a replacement for Coumadin (warfarin), which has been the go-to anticoagulant treatment for decades. The drug is part of a new-generation of treatments designed to avoid blood clots among individuals at risk for deep vein thrombosis or pulmonary embolism, which has been promoted as easier to use than warfarin. However, it has been linked to a large number of bleeding problems.

    Each of the lawsuits involved in the Xarelto MDL raise nearly identical allegations, indicating that users and the medical community were provided inadequate warnings about the potential bleeding side effects of Xarelto, as well as the fact that the new-generation anticoagulant lacked a safe and effective reversal agent to allow doctors to quickly stop the blood thinning effects of the drug.

    One of the more recent lawsuits was filed earlier this week, involving claims for nine different plaintiffs, each involving allegations that severe injuries were caused by uncontrollable bleeding on Xarelto, including at least one wrongful death claim.

    The complaint (PDF) was brought on behalf of individuals from across the U.S., including Alfred Klein, of New York; Beatrice McCall, of Alabama; Helen Maestas, of New Mexico; Perry Middleton, of Colorado; Richard Montigne, of Arizona; Tracy Patton, of North Carolina; Brenda Rogers, of Texas; David Vickery, also of Texas; and New York resident John Sturtevant, whose wife died of internal bleeding after using the drug.

    “Plaintiffs bring this case against Defendants for damages associated with ingestion of the pharmaceutical drug Xarelto,” the lawsuit states. “Specifically, Plaintiffs suffered various injuries, serious pain and suffering, medical, hospital and surgical expenses, loss of consortium, and/or death and funeral expenses as a direct result of their use of Xarelto.”

    The factual patterns provided by each of the nine plaintiffs are similar, indicating that uncontrollable bleeding occurred after taking Xarelto for periods ranging from five days to twelve months. Among the injuries suffered by plaintiffs are intracerebral hemorrhaging oral bleeding, gastrointestinal bleedings and other internal bleeds, as well as strokes and heart failure.

    Lack of Reversal Agent with Xarelto

    While all blood thinners carry a risk of bleeding injury, the side effects of warfarin can be quickly reversed with a widely known antidote of bleeding occurs. However, there was no Xarelto reversal agent when the drug was introduced. Plaintiffs allege that the drug makers failed to adequately warn doctors about the lack of an antidote.

    “Importantly, Xarelto’s significant risk of severe, and sometimes fatal, internal bleeding has no antidote to reverse its effects, unlike warfarin,” the lawsuit (PDF) filed earlier this week states. “Therefore, in the event of hemorrhagic complications, there is no available reversal agent. The original U.S. label, approved when the drug was first marketed, did not contain a warning regarding the lack of antidote, but instead only mentioned this important fact in the overdose section.”

    Similar claims were raised in the litigation over Pradaxa, which is another new-generation anticoagulant introduced in October 2010, one year before Xarelto hit the market.

    More than 4,000 Pradaxa lawsuits were ultimately filed by users of that drug who suffered bleeding injuries. Following several years of litigation, the manufacturer of that medication ultimately agreed to pay $650 million in Pradaxa settlements, with an average of about $150,000 per claim.

    As Xarelto bleeding lawyers continue to review potential cases for individuals prescribed the anticoagulant throughout the United States, it is expected that this litigation will involve many more cases than the Pradaxa litigation, as the drug has become more widely used in recent years.

    http://www.aboutlawsuits.com/2400-xarelto-lawsuits-91481/
    

    Return to headline | Return to top

23. Xarelto Bleed Injury Timeline Updates and Patient Information

    Dec 20, 2015 | Prescription Drug Injuries

    By Lieff Cabraser

    Xarelto was released in July 2011 to prevent blood clots in patients undergoing knee and hip surgeries, and its use was then expanded to include patients with irregular heartbeats or facing likely lung and leg blood clots. It was also used to prevent clots in some people with atrial fibrillation. The drug is taken as a pill with the chemical name rivaroxaban. The new Xarelto patient information injury and lawsuit timeline shown below tracks Xarelto from its release to thousands of patient injury reports less than two years later, to thousands of Xarelto death and uncontrolled bleeding injury lawsuits slated for bellwether treatment in 2016 and 2017.

    Contact Lieff Cabraser

    Lieff Cabraser represents patients prescribed Xarelto sold in the U.S. by Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson ("J&J"). Our law firm has been recognized by U.S. News, Best Lawyers, and the National Law Journal as one of the top plaintiffs' law firms in the nation. Please contact us by completing our contact form or calling us toll-free at 1 888-321-1510.

    http://www.lieffcabraser.com/blog/2015/12/xarelto-bleed-injury-timeline-updates-and-patient-information.shtml
    

    Return to headline | Return to top

24. NJ Man Sues Drug Companies Over Xarelto Side Effects

    Dec 21, 2015 | Righting Injustice

    By Jennifer Walker-Journey

    A New Jersey man is suing the makers of the blood thinner Xareltoclaiming the drug companies did not warn the public about life threatening side effects.

    Stuart Elfenbein’s lawsuit names Johnson & Johnson unit Janssen Pharmaceuticals, Bayer Healthcare and their partner companies, alleging fraud and negligence.

    According to his complaint, Elfenbein suffered serious gastrointestinal bleeding on Feb. 28, 2014, six months after starting treatment with Xarelto. His lawsuit claims he suffered severe, permanent injuries; emotional distress, loss of earnings, and medical expenses.

    Xarelto, known chemically as rivaroxaban, is used to prevent strokes in patients with the common heart rhythm abnormality atrial fibrillation. It is also used to prevent and treat deep vein thrombosis and pulmonary embolism, and to prevent blood clots in patients who have recently undergone hip or knee replacement surgery.

    Xarelto is in a new class of blood thinners known as factor Xa inhibitors, which were developed to go head-to-head with the long used anticoagulant warfarin. All blood thinners carry a risk for serious and uncontrolled bleeding events, including gastrointestinal bleeds and brain hemorrhages, both of which can be fatal.

    Dozens of lawsuits targeting Xarelto allege that the drug companies did not adequately warn about the bleeding risks with Xarelto.

    Xarelto was approved in 2011, just a year after the first factor Xa inhibitor, Pradaxa, hit the market. Pradaxa maker Boehringer Ingelheim was also slapped with lawsuits after patients suffered serious and sometimes fatal internal bleeds. Boehringer Ingelheim ultimately agreed to pay $650 million to settle thousands of Pradaxableeding risks lawsuits.

    http://www.rightinginjustice.com/news/2015/12/21/nj-man-sues-drug-companies-over-xarelto-side-effects/
    

    Return to headline | Return to top

25. Xarelto Lawsuit: Georgia Woman Claims Serious Internal Bleeding Injury

    Dec 21, 2015 | Top Class Actions

    By Ashley Vanover

    A Xarelto bleeding lawsuit was filed against drug manufacturers Bayer Healthcare and Janssen Pharmaceuticals alleging they failed to provide adequate warnings about the safety risks associated with the use of the popular blood thinner.

    A Georgia resident alleges the companies failed to warn patients and provide information to physicians related to theincreased risks of internal bleeding events associated with taking Xarelto.

    According to the Xarelto lawsuit, plaintiff Marie B., Bayer and Janssen negligently promoted Xarelto as safe when they allegedly knew the blood thinner could cause life-threatening internal bleeding.

    Marie is seeking financial compensation for her Xarelto lawsuit to be included in the multidistrict litigation currently pending in Louisiana federal court.

    What is Xarelto?

    Xarelto is the brand name of the anti-coagulant medication, rivaroxaban.  It is a blood-thinner or oral anti-coagulant that is manufactured by Bayer HealthCare, the pharmaceutical division of Bayer AG, a Germany-based healthcare products manufacturer.

    It is marketed in the United States by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, the largest manufacturer of pharmaceuticals and medical products in the world.

    Xarelto is used to treat patients who have had blood clots such as deep vein thrombosis and pulmonary embolism to prevent them from reoccurring.

    It is also used to reduce the risk of blood clot formation and stroke in patients with atrial fibrillation or rapid heartbeat that is not related to a heart valve problem and in patients who have had knee or hip replacement surgery.

    Xarelto is a competitor drug of Pradaxa which is manufactured by another German drug maker, Boehringer Ingelheim but Pradaxa works differently than Xarelto.

    Xarelto and Pradaxa were meant to replace older anticoagulants such as heparin and warfarin (Coumadin) without requiring laboratory testing of the drug’s clotting ability in a specific patient at a particular dose.

    Serious Xarelto Side Effects

    Xarelto may also cause more serious side effects, usually related to internal bleeding and the inability to form blood clots at all.  Severe and serious side effects have contributed to the occurrence of death in some patients.

    An internal bleed may develop in any part of the body and will continue until the drug is discontinued and cleared from the system.  Unlike other anticoagulant medications such as warfarin, there is no antidote for Xarelto related bleeding.

    Bleeding may become a serious or life threatening condition if it occurs close to a major organ like the lungs, kidneys, liver, or brain.  Uncontrolled bleeding will mean that the organ is not receiving adequate blood flow to provide oxygen and nutrients and may cause significant organ damage.

    In addition, uncontrolled internal bleeding may cause blood pooling within the abdominal and other areas which can result in additional risks such as pain, organ compression, and infection.

    Xarelto Injury Lawsuits

    The Xarelto injury lawsuit is seeking compensatory, economic, and punitive damages for the drug companies’ alleged fraudulent and reckless disregard for the safety and welfare of Xarelto users like Marie.

    Marie’s individual Xarelto Lawsuit is Case No. 2:15-cv-02187-EEF-MBN and the Xarelto MDL is In re: Xarelto (Rivaroxaban) Products Liability Litigation, Case No. 2592 in the U.S. District Court for the Eastern District of Louisiana.

    http://topclassactions.com/lawsuit-settlements/lawsuit-news/242184-xarelto-lawsuit-georgia-woman-alleges-serious-internal-bleeding-injury/
    

    Return to headline | Return to top

26. More Lawsuits and Clinical Research Involving Xarelto

    Dec 21, 2015 | Xarelto Lawyer

    Rivaroxaban, the anticoagulant medication that is more commonly known as Xarelto, continues to make legal and medical headlines in 2015.

    In late November, a woman from Pennsylvania filed a lawsuit against Janssen Pharmaceuticals and various business units of Bayer Healthcare. The civil complaint alleges that Janssen and Bayer distribute Xeralto as a medication that can be safely used to lower the risk of complications related to blood clots.

    According to local newspaper The Madison Record, Elaine Bell's complaint explains that she took Xarelto to prevent dangerous health conditions such as embolisms and strokes; alas, Ms. Bell alleges that she ended up bleeding profusely while taking the medicine in question. In addition to the bleeding, Ms. Bell explains that she suffered pain and anguish, which in turn forced her to take time off from her job so that she could seek medical attention.

    Ms. Bell seeks to recover $50,000 in damages, court costs and legal fees from each of the Bayer and Janssen business units she is suing, which add up to nine collective defendants.

    Can Xarelto Reduce the Length of Hospital Stays?

    Patients who take Xarelto while hospitalized could go home sooner, at least according to a research study published in the Lancet Hematology journal.

    During the annual meeting of the American Society of Hematology, pharmaceutical giants Janssen and Bayer presented a study that focused on the use of Xarelto for the treatment of deep vein thrombosis.

    The longitudinal research looked at inpatient hospital records of 5,000 individuals treated for vein thrombosis, and who took Xarelto as part of their treatment plan. This data was compared to a previous international study that focused on vein thrombosis patients who took traditional anticoagulant medications while hospitalized.

    The Janssen/Bayer research found that patients who took Xarelto were discharged from the hospital within five days on average. This was certainly an improvement over patients who took traditional medications since they stayed more than seven days on average.

    Furthermore, the Xarelto study found that fatal bleeding conditions developed in less than one percent of patients. A little over two percent of patients who took standard anticoagulant medicines suffered fatal bleeding episodes.

    Although the Janssen/Bayer study found safer and more efficient results in patients taking Xarelto, the pharmaceutical giants have been named in hundreds of lawsuits related to adverse effects and dangerous bleeding.

    http://xareltolawyer.com/articles/more-lawsuits-and-clinical-research-involving-xarelto/
    

    Return to headline | Return to top

27. Xarelto Bellwether Update – Lawyer Referral

    Dec 21, 2015 | Pravati Networks

    United States District Judge Eldon Fallon is overseeing the Xarelto Lawsuit bellwether trials. Fallon issued a recent order stating that a group of 40 filed lawsuits will be selected in January 2016. After the selection the first 2 of 4 bellwehter trials will take place in the U.S. District Court of the Eastern District of Louisiana on February 6th, 2017, and March 13th, 2017. The third Xarelto bellwether trial is to be heard in Mississippi on April 24th, 2017, while the fourth and final bellwether trial will be heard in Texas on May 30th, 2017.

    Currently, there are 1,700 Xarelto Lawsuits filed against the defendant’s and manufacturers Bayer AG and Janssen Pharmaceuticals. The filed lawsuits we formed into MDL 2592 and all allege that the blood-thinning drug caused uncontrollable bleeding events.

    Xarelto Lawsuits and Legal Funding

    If you or a loved one was injured by an uncontrollable bleeding event while taking Xarelto, please contact us today. Our expert Xarelto lawyers are standing by and ready to fight for your settlement. Besides lawyer referral, we also provide pre-settlement funding for your Xarelto Lawsuit.

    http://www.pravatinetworks.com/xarelto-bellwether-update-lawyer-referral/
    

    Return to headline | Return to top

28. Blood Thinner Lawsuit

    Dec 22, 2015 | My Drug Justice

    By Baron & Budd

    Blood Thinner Lawsuit

    If you have suffered a stroke, have heart disease or have a condition that affects your blood vessels, you may be prescribed a blood thinner such as Xarelto or Pradaxa, known as an anticoagulant. This type of medication is designed to reduce the risk of another stroke or a heart attack by lowering the chances a blood clot will form in a vein or an artery. Blood thinners are also commonly prescribed for patients with congenital heart defects, atrial fibrillation (an abnormal heart rhythm), or those who have undergone heart valve surgery.

    Unfortunately, use of Xarelto and Pradaxa can often result in severe complications. If you or a loved one has been harmed after the use of one of these medications, an attorney with Baron & Budd may be able to help.

    The Dangers of Xarelto and Pradaxa

    Xarelto and Pradaxa are among the “new generation” of blood thinners that have been introduced to the market in the last few years. They are marketed as an alternative to Coumadin, the brand name of the drug Warfarin. Unlike patients taking Coumadin, Xarelto and Pradaxa users do not have to be monitored nearly as often.

    The problem with these new blood thinners is that, while all of these types of medications present the risk of excessive bleeding, the threat is particularly acute with Xarelto and Pradaxa. The reason is that doctors can administer large doses of vitamin K or frozen plasma to patients taking Coumadin who experience excessive bleeding events. These agents thicken the blood and stop hemorrhaging. However, there is no such antidote for those taking the newer blood thinners.

    As a result, patients who use Xarelto and Pradaxa are at a dangerous risk of severe – potentially even fatal – internal or excessive bleeding. In addition, some patients taking these drugs have also suffered liver damage, kidney failure, brain hemorrhage and more.

    Comparing Coumadin With the “New Breed” of Blood Thinner

    Warfarin was approved in 1954 by the U.S. Food and Drug Administration in order to prevent strokes. Many patients have used it over the years very effectively to treat several medical conditions, such as blood clots in the legs (deep vein thrombosis), pulmonary embolism (blood clots in the lungs), atrial fibrillation and mechanical heart valves.

    While the drug has a long track record of effectiveness, there are certain drawbacks to taking the medication. The biggest is that it can be hard for a doctor to prescribe the right dosage. If he or she prescribes too much, there is a high risk of dangerous bleeding. But if not enough is prescribed, then a stroke risk will remain. Also, patients on Coumadin must have monthly blood tests in order for a doctor to be certain the drug is working properly. Patients also have to closely monitor their intake of foods such as green leaf lettuce and spinach, which have a great deal of vitamin K. If someone has too much vitamin K in his or her system, the medication will not be effective.

    Xarelto and Pradaxa, on the other hand, do not require constant medical monitoring. Both drugs are touted as having the same ability as Coumadin to reduce the risk of stroke. However, again, if a patient goes through an excessive bleeding event there will be no way to stop it. There is no available antidote for either drug.

    There are a lot of variables that go into determining how long a patient will need to take a blood thinner. While some people need to take them for the rest of their lives, others may only need them for a few weeks. The risk of forming new blood clots will be the main factor in a doctor’s decision as to whether or not to keep a patient on this type of drug.

    Anyone considering the use of a blood thinner must carefully weigh the risks and benefits of all anticoagulants on the market. They will need to tell their doctor about all of the medications they are taking as well, because certain medications may present the risk of potentially dangerous drug interactions.

    https://baronandbudd.com/mydrugjustice/blood-thinner-lawsuit/
    

    Return to headline | Return to top

29. Xarelto Internal Bleeding Incidents Lawsuit In New Mexico

    Dec 22, 2015 | Blood Thinner Help

    By Joseph Osborne

    Xarelto is an anticoagulant produced by pharmaceutical companies, Bayer and Johnson & Johnson. This blood thinner has been highly publicized and endorsed by big names like Arnold Palmer and ten-time NBA All-Star Chris Bosh.

    Xarelto is a blood thinner that is prescribed in order to prevent life threatening blood clots that will likely create a blood flow blockage in the body. Unfortunately, Xarelto has been connected with a heightened chance of a user experiencing serious negative side effects like uncontrollable internal bleeding that can result in death or serious injury to the user.

    This has led to many people filing Xarelto related lawsuits all across the United States.

    Xarelto Has Been Linked To Serious Internal Bleeding

    Xarelto was originally permitted for use by the Food and Drug Administration (FDA) in 2011 and then safety information was later changed in 2014 to highlight updated Adverse Reactions that include severe bleeding. The FDA first approved Xarelto to be used to prevent blood clots in people who have been diagnosed with deep vein thrombosis (DVT), Atrial Fibrillation (AFib), PE, stroke, and in people who have had hip or knee replacement surgery.

    There have been medical studies performed that have correlated Xarelto usage with serious unfavorable side effects that in some cases have led to a patient sustaining grave injuries and in the worst cases, the death of a patient.

    The most frequently documented adverse effect that results in injury, has been internal bleeding that cannot be reversed, such as gastrointestinal bleeding, brain hemorrhage, heart attacks and strokes, and pulmonary embolisms. All of these adverse effects have been reported by some people using Xarelto.

    For more information about Xarelto’s side effects on a user please see our Xarelto side effects and risks page here.

    Possible Incidents Of Xarelto Internal Bleeding Injuries In New Mexico

    New Mexico’s current 2014 census data, records that a total of 2,085,572 people live there. Our Xarelto team compared the nationwide overall total of Xarelto prescriptions from the time it was approved in America (2011), with the total number of New Mexico residents, as well as New Mexico residents in the five largest cities. Our team did this in an effort to work out the likely number of incidents of New Mexico residents who have experienced the severe side effects that Xarelto can cause. From this comparative calculation, we worked out that 1,223 New Mexico residents suffered some form of negative internal bleeding injury due to Xarelto usage.

    Here are the New Mexico five largest populations we used in our calculations:

    Albuquerque- population 557,169

    Las Cruces- population 101,408

    Rio Rancho- population 93,820

    Santa Fe- population 70,297

    Roswell- population 48,608

    Below are the possible internal bleeding incidents in the New Mexico’s five major cities:

    Albuquerque- 327

    Las Cruces- 59

    Rio Rancho- 55

    Santa Fe- 41

    Roswell- 28

    Taking Action To File A Case

    If you or someone close to you used Xarelto for the prevention of blood clots but ended up suffering a stroke, a heart attack or there was a major internal bleed that took place because there was no way to stop the effects of the anticoagulant, then you may have a Xarelto lawsuit to file.

    We understand that this is a very delicate and often times difficult circumstance. If you have questions pertaining to your specific case or circumstance, we encourage you to get hold of us as soon as you can. Our Xarelto attorneys are here to answer your questions at any time of the day or night. Our attorneys also offer a no cost consultation to discuss your case specifics.

    We encourage you to also visit our Frequently Asked Questions to help you navigate your case questions a bit more as well.

    Who Will Be In Charge Of My Lawsuit?

    Your Xarelto lawsuit is in good hands. Our Xarelto attorneys have an abundance of experience in working on cases that involve large pharmaceutical companies.  At the moment our attorneys are taking cases from individuals from all over America including New Mexico.

    If you are ready to take the next step in bringing your case to court and file a lawsuit, our Xarelto lawyers will help you proceed confidently.

    Once you are ready to file your case, contact us here and we will get you the justice you deserve.

    New Mexico Emergency Resources

    If you believe you may be experiencing some of the side effects mentioned above in connection with Xarelto intake, contact emergency services immediately.

    Below are some of the hospitals you can visit in New Mexico if you are having Xarelto related negative effects:

    Presbyterian Hospital

    1100 Central Avenue SE
    Albuquerque, NM 87106-4934

    (505) 841–1234

    Christus St. Vincent Regional Medical Center

    455 St. Michael’s Drive
    Santa Fe, NM 87505-7663

    (505) 983–3361

    Eastern New Mexico Medical Center

    405 West Country Club Road
    Roswell, NM 88201-5209

    (575) 622–8170

    http://bloodthinnerhelp.com/new-mexico-xarelto-lawsuit/
    

    Return to headline | Return to top

30. Xarelto Lawsuit Plaintiffs Point To Studies That Raise Excessive Bleeding Concerns

    Dec 23, 2015 | Mass Tort Nexus

    By Joseph Osborne

    Two studies have brought new concerns to light regarding blood-thinner Xarelto and dangerous, uncontrollable bleeding episodes. Each study appears to link the anticoagulant to serious and even fatal side effects for patients taking it.

    Xarelto was initially approved by the U.S. Food and Drug Administration in 2011, and was released to the market as a revolutionary new blood thinner. It was originally approved specifically to treat patients who had recently undergone hip or knee replacement surgeries, and this approved use was later expanded, approving the drug for patients with atrial fibrillation, pulmonary embolism, or deep vein thrombosis.

    After only its first year on the market, the drug quickly became considered one of the most dangerous blood thinners. It was suddenly linked to hundreds of reports of adverse events, with patients claiming it had caused them blood clots, strokes, pulmonary embolisms, and other serious complications.

    Eye bleeding

    One study that illustrates problems with the drug was done by doctors Judy H. Hun and John C. Hwang. They noted that three of their patients had developed “spontaneous vitreous hemorrhage” (also known as eye bleeding) while using Xarelto. The doctors’ studies also concluded that the risk of eye bleeding may be increasingly elevated for patients who had switched from a traditional blood thinner, such as warfarin, to Xarelto.

    Another study took place from October 1st 2010 to March 31st, 2012, and evaluated many people from the U.S. who were using Xarelto, Pradaxa, and Warfarin as blood thinners. The study details note that their final sample of patients included 46,000 total, 39,607 of which used warfarin, 4,907 of which used Pradaxa, and 1,649 of which used Xarelto. Research done on these individuals highlighted “as much as a 50% increase in the risk of gastrointestinal bleeding with dabigatran compared with warfarin or a more than twofold higher risk of bleeding with rivaroxaban (Xarelto) when compared with warfarin.”

    Lawsuits filed against Xarelto now number near 2,000 in federal court. They have been consolidated to form multidistrict litigation number 2592, and are being overseen by Judge Eldon Fallon in the Eastern District of Louisiana. As they await trial, their numbers are only expected to increase.

    http://www.masstortnexus.com/mass-torts-news/xarelto-studies-excessive-bleeding-concerns/
    

    Return to headline | Return to top

31. Xarelto Bleeding Lawsuit Claims Wrongful Death of Grandmother

    Dec 23, 2015 | Top Class Actions

    By Ashley Vanover

    Bayer and Johnson & Johnson Pharmaceuticals are facing a wrongful death lawsuit, alleging that their blood thinner Xarelto (also known as rivaroxaban) is dangerous and should not be sold.

    The surviving granddaughter of a Louisiana woman filed a Xarelto wrongful death lawsuit in November on behalf of her deceased grandmother, Hattie G.

    Her Xarelto lawsuit is against Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, and the co-marketer of Xarelto, and Bayer Healthcare AG, alleging these companies failed to warn patients and physicians of the increased risks of irreversible and fatal internal bleeding when using Xarelto.

    Plaintiff Ashlie F. alleges in the Xarelto lawsuit that her grandmother Hattie used Xarelto in September 2014 to treat her deep vein thrombosis and subsequently, on Nov. 10, 2014, suffered a fatal intracranial bleed that was allegedly a direct result of the drug.

    The Xarelto lawsuit claims that Bayer and Janssen Pharmaceuticals knew of the Xarelto side effects and continued to sell it despite the dangerous risks.

    Serious Side Effects of Xarelto

    Xarelto (rivaroxaban) is an oral anti-clotting medication or “blood thinner,” which is prescribed to prevent and to treat deep vein thrombosis (blood clots in the legs) and pulmonary embolism (blood clots in the lungs), and to reduce the risk of stroke in some patients with a common heart arrhythmia known as atrial fibrillation.

    It may also be prescribed to patients undergoing knee or hip replacement surgery to prevent clots from forming in the legs and traveling to the lungs.

    The FDA approved Xarelto to reduce the risk of deep vein thrombosis and pulmonary embolism in July 2011. The FDA also approved Xarelto for reduction of stroke risk in certain patients with atrial fibrillation in November 2011. The FDA then expanded its approval to the ongoing treatment and prevention of deep vein thrombosis and pulmonary embolism in November 2012.

    In 2013, the Institute for Safe Medication’s Practice QuarterWatch reported a steady increase in adverse events reported to the FDA for Xarelto.

    In January 2014, the FDA’s safety surveillance agency announced a plan to monitor and study Xarelto for serious events such as ischemic strokes, intracranial hemorrhages, and gastrointestinal bleeding. There is currently no reversal agent for Xarelto bleeds.

    Injuries that can occur when using Xarelto include:

    Stroke

    Gastrointestinal bleeding

    Cerebral hemorrhage

    Uncontrolled hemorrhageInternal bleeding

    Death

    Signs and symptoms of a Xarelto injury may include:Stroke (bleeding into the brain)Unusual bleeding

    Discolored urine (blood in the urine)Red or black-colored stool (blood in bowel movements)Coughing up blood

    Vomiting blood that looks like “coffee grounds” or is bright redFrequent nose bleed or gum bleeding

    Weakness and swelling in the extremities

    Neurological injury (bleeding around spinal cord)

    Xarelto Lawsuits

    The Xarelto lawsuit is seeking compensatory, economic, and punitive damages for Bayer’s and Janssen Pharmaceutical’s alleged deceptive and reckless practices in misrepresenting and omitting numerous facts about the dangers of taking Xarelto and causing the death of Hattie G. in part by their gross negligence.

    The Xarelto Wrongful Death Lawsuit is Case No. No. 2:15-cv-05874 in the U.S. District Court, Eastern District of Louisiana. It will join about 1,700 claims pending in a federal multidistrict litigation (MDL), which is currently centralized for pretrial proceedings before U.S. District Judge Eldon Fallon.

    http://topclassactions.com/lawsuit-settlements/lawsuit-news/247083-granddaughters-xarelto-lawsuit-claims-wrongful-death-of-grandmother/
    

    Return to headline | Return to top

32. Xarelto Bleeding Death Lawsuit Filed in Louisiana

    Dec 24, 2015 | Dallas Fort Worth Injury Lawyer

    By Dr. Shezad Malik

    Ashlie Fluitt from Louisiana,  filed a wrongful death claim on behalf of her grandmother who died as a result of catastrophic side effects from using Xarelto. Fluitt alleges that Xarelto anticoagulation medication caused severe brain bleeding which caused her grandmother to die.

    Fluitt filed her lawsuit in the U.S. District Court for the Eastern District of Louisiana claiming that Hattie Deville-Goodwin’s death was caused by the drug manufacturers’ failure to warn about the uncontrollable bleeding side effects associated with the new-generation anticoagulant or blood thinner Xarelto.

    Deville-Goodwin took Xarelto for treatment of deep vein thrombosis or blood clot in her leg. Two months later, Deville-Goodwin developed severe bleeding in the brain, and died shortly afterwards from the deadly intracranial hemorrhage.

    Many lawsuits have been filed against Xarelto’s manufacturers,  Bayer and Johnson & Johnson and the plaintiffs claim that the companies failed to warn patients and doctors about the risks associated with Xarelto and the lack of an antidote to help stop the bleeding.

    Since December 2014, all federal product liability lawsuits filed against Bayer and Johnson & Johnson over the bleeding side effects of Xarelto have been centralized and consolidated before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana as part of an MDL, or multidistrict litigation.

    Lawsuits against Bayer and Johnson & Johnson are consolidated in two courts, a multidistrict litigation court in the Eastern District of Louisiana and a mass tort litigation court in Philadelphia.

    The MDL in Louisiana contains over 2,400 federal lawsuits, and the mass tort in Philadelphia contains more than 500 state lawsuits.

    4 Xarelto Bellwether Trials Set

    Judge Fallon set a series of four bellwether trials to go before juries in the Spring of 2017. The number of Xarelto lawsuits continue to increase and be filed by individuals across the United States, alleging severe and deadly bleeding complications.

    Bellwether Trials in Louisiana, Mississippi and Texas

    The first two trials will be held in the Eastern District of Louisiana, on February 6 and March 13, 2017. The third trial will be held in Mississippi on April 24, 2017 and the fourth trial will be held in Texas on May 30, 2017.

    According to Judge Fallon’s order, the cases that will go before juries on these dates will be pulled from a pool of 40 lawsuits to be selected in January 2016. These cases will be trial ready, with case-specific discovery, including depositions of plaintiffs, prescribing doctors, treating physicians and sales representatives of the drug makers.

    What is Xarelto?

    Xarelto (rivaroxoaban) was released and approved for sale in 2011 as a superior replacement for Coumadin (warfarin). Xarelto is used to reduce the risk of blood clots among patients at risk for deep vein thrombosis, pulmonary embolism and those patients at risk for a stroke with atrial fibrillation.

    Atrial fibrillation is a common heart rhythm problem, which leads to embolic strokes, from blood clots that develop in the heart and travel up to the brain.

    Xarelto was developed and sold jointly by Johnson & Johnson’s Janssen Pharmaceuticals subsidiary and Bayer Healthcare. Xarelto is a “direct thrombin inhibitor,” and Xarelto was released to compete with Boehringer Ingelheim’s Pradaxa, another new type of anticoagulant. Both drugs were touted as being superior and easier to use than the older blood thinner warfarin, also known as Coumadin. Coumadin was the gold standard for anticoagulants and dominated the blood thinner market for several decades.

    Xarelto has the largest share of the market for anticoagulants and is considered a blockbuster drug, with annual sales over $1 Billion in the United States.

    Big Problem: No Xarelto Antidote

    All anticoagulants or blood thinners have a risk of bleeding and injury, but Xarelto has been linked to a significant number of injuries involving catastrophic and uncontrollable bleeds, including death.

    Xarelto has been advertised heavily as being easier to use than warfarin, since it does not require regular blood monitoring. According to  several recent studies, those claims may be in doubt.  Medical researchers have indicated that Xarelto blood monitoring may actually help doctors identify patients at the greatest risk of bleeding.

    Plaintiffs are filing bleeding lawsuits claiming that the drug manufacturers suppressed information about the lack of a reversal agent. Warfarin’s blooding thinning effects can be quickly reversed in an emergency, there is no antidote for Xarelto.

    Similar Lawsuits Claims Settled For Pradaxa

    Pradaxa, is another new-generation anticoagulant introduced by Boehringer Ingelheim in October 2010. In 2014, there were 3,592 serious adverse event reports involving Pradaxa, with 752 involving the death of the patient, compared with 3,331 reports associated to Xarelto bleeding problems, with 379 involving a patient death.

    Similar allegations of a lack of an antidote, were raised in more than 4,000 Pradaxa lawsuits. On the eve of trial, Boehringer Ingelheim agreed to pay $650 million in Pradaxa settlements, with an average of about $150,000 per claim.

    http://www.dallasfortworthinjurylawyer.com/2015/12/xarelto-bleeding-death-lawsuit-filed-louisiana.html
    

    Return to headline | Return to top

33. Xarelto Side Effects & Lawsuit Information

    Dec 24, 2015 | Active Health News

    Xarelto is a blood-thinning drug, or anticoagulant. The U.S. Food and Drug Administration (FDA) approved Xarelto in July 2011, and its sales have steadily grown since then. While bleeding is a common complication associated with anticoagulants, it has been alleged that Xarelto is more dangerous than traditional blood thinners because no antidote exists to reverse its blood-thinning side effects.

    Xarelto Bleeding Lawsuit

    Many patients who suffered Xarelto bleeding-related injuries, strokes, pulmonary embolisms, deep vein thrombosis, and heart attacks have filed a Xarelto bleeding lawsuit. Most of these Xarelto bleeding lawsuits are product liability bleed lawsuits against the manufacturers Johnson & Johnson and Janssen Pharmaceuticals. The manufacturers of other, similar blood-thinning drugs face similar Xarelto bleeding lawsuits. Thousands have filed Xarelto bleeding lawsuits against Boehringer Ingelheim. These lawsuits are quite similar and more numerous, and may provide an early glimpse of the future of Xarelto bleeding lawsuits.

    While people file lawsuits for many reasons, the most prominent reason is to recover financial compensation for a patient’s injuries. Xarelto injuries can require lengthy hospitalization, significant long-term health care costs, and substantial time away from work. Product liability Xarelto bleeding lawsuits exist in large part to shift the burden of these costs to manufacturers. For many families, filing a Xarelto bleeding lawsuit can be the difference between financial hardship and making ends meet.

    Xarelto Bleeding Attorney

    Patients who are injured from Xarelto side effects should consult with a Xarelto bleeding attorney to learn more about their legal options. The Rottenstein Law Group is a great Xarelto bleeding attorney who are reviewing claims of uncontrollable Xarelto bleeding side effects that might give rise to Xarelto bleeding lawsuits.

    Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several xarelto lawsuits from a leading Xarelto bleeding attorney alleging that Xarelto side effects are dangerous and defective. Plaintiffs in the Xarelto bleeding lawsuit allege serious and fatal injuries, including cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug Xarelto. If you or a loved one suffered from one or more of these Xarelto side effects while taking Xarelto, and you wish to discuss your case with a Xarelto bleeding attorney.

    What are the Side Effects of Xarelto?

    Xarelto Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects of Xarelto when taking this medication.

    Xarelto side effects include easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), bleeding from wounds or needle injections, any bleeding that will not stop. Heavy menstrual periods is a dangerous Xarelto side effect. Other Xarelto side effects include black or bloody stools, coughing up blood or vomit that looks like coffee grounds.

    Less serious Xarelto side effects may include: muscle pain, itching and pain in arms or legs. However, the most common adverse Xarelto side effects are bleeding complications, including major bleeding events. Fainting, itching, and muscle spasms have been reported. Some blood thinning antibiotics, antifungal medications, anticoagulants, blood thinners, NSAIDs, and aspirin may have adverse interactions and cause further Xarelto side effects.

    http://activehealthnews.com/xarelto-side-effects-lawsuit-information/
    

    Return to headline | Return to top

34. Judge Stipulates Xarelto Injury Types for Bellwether Trials

    Dec 29, 2015 | Drug Reporter

    By Katarina Siegfeld

    The presiding judge in the coordinated Xarelto lawsuit proceedings has issued a case management order stipulating the injury categories into which cases must be grouped to be considered for potential bellwether trials, which are expected to take place in 2017 as part of the multidistrict litigation (MDL 2592) created to manage thousands of cases related to the anticoagulant (or blood thinner) alleged to cause serious bleeding problems.

    U.S. District Judge Eldon Fallon issued Case Management Order No. 4 on December 17 to outline the next steps in the discovery process for the MDL, which is taking place in the Eastern District of Louisiana. The bellwether trials will help to determine a jury’s response to the evidence presented, set precedent for future trials, and encourage large-scale settlements. Participants are engaged in a general discovery process to apply to all cases at this time. However, by issuing the order related to possible injury categories, Judge Fallon sets up a pool of potential lawsuits that will be representative of distinct types of injuries or circumstances that inform specific subcategories of lawsuits.

    Xarelto lawsuits grouped according to injury type, reason for prescription

    Judge Fallon broke down categories for Xarelto lawsuits in connection to type of injury and reason for prescription. Injury types include:

    Gastrointestinal bleeding

    Rectal bleeding

    Brain bleed/hemorrhagic stroke

    Each lawsuit proposed as a bellwether case is to be classified according to the most serious injury (i.e. gastrointestinal bleeding rather than nosebleed, if both were alleged as injuries in a single case). Reasons for prescribing Xarelto were reducing the risk of stroke, treating deep vein thrombosis, or treating pulmonary embolism.

    Both the defense and plaintiffs are to put forward 10 possible cases to be included in the bellwether pool by January 11, with specific quotas for cases based on state of origin. Both sides are encouraged to pick cases that fit each of the categories outlined above, though there is no specific requirement that they do so. The Court itself will also add twenty cases to the pool by January 15. Bellwether trials are expected to take place between February and May of 2017.

    Thousands of lawsuits filed over Xarelto injuries

    Over 2,400 federal lawsuits have been filed over Xarelto-related bleeding injuries alleged by plaintiffs. The drug (also known by the generic name rivaroxaban) was put on the market in 2011 and touted as a superior treatment compared to the standard blood-thinner, Coumadin. It was purportedly easier to use and more effective, requiring less frequent testing and less arduous lifestyle modification.

    However, subsequent studies have called into question many of the initial claims put forward aboutXarelto, including the claim that frequent testing is unnecessary or that the drug is safer or more effective than the older alternative. Most problematic is the fact that Xarelto lacks an antidote should a hemorrhage take place, leading doctors with few options to treat a life-threatening bleed in the brain and gastrointestinal tract. Coumadin, in contrast, could generally be reversed with a dose of Vitamin K.

    http://drugreporter.com/2015/12/judge-stipulates-xarelto-injury-types-bellwether-trials/
    

    Return to headline | Return to top

35. Xarelto Lawsuits Show No Sign of Stopping

    Dec 29, 2015 | LawyersandSettlements.com

    By Heidi Turner

    Xarelto lawsuits alleging patients suffered severe bleeding events after using the anticoagulant drug show no signs of stopping, with 2,400 lawsuits now sitting in the multidistrict litigation for pretrial proceedings. Plaintiffs say they were not warned Xarelto had no antidote and were not warned about the risks of a serious bleeding event while taking Xarelto.
    
    According to reports from the Judicial Panel for Multidistrict Litigation (JPML), as of December 15, 2015, there were 2,400 lawsuits consolidated for pretrial proceedings in MDL 2592 (In Re: Xarelto (Rivaroxaban) Products Liability Litigation, before US District Judge Eldon E. Fallon). Although the growth of the MDL has slowed down somewhat from October, there is still a significant number of lawsuits added to the MDL monthly. As of November 16, 2015, there were 2,266 lawsuits consolidated, which was up from the 1,698 lawsuits consolidated by mid-October.
    
    Lawsuits allege patients were not warned that Xarelto, unlike Coumadin, did not have an antidote to the drug’s anticlotting mechanism. Xarelto is an anticoagulant, used to reduce the risk of blood clots and strokes. But it, like its predecessor Coumadin, is associated with an increased risk of serious bleeding events due to its anticlotting properties.

    Coumadin, which has been on the market for decades, has an antidote in the form of vitamin K. Patients who experienced a bleeding event and received medical attention in time could end the bleeding event. But patients on newer anticoagulants - including Xarelto - currently have no accepted antidote. That means if they experience a bleeding event, they have to wait for the drug to leave their system. Plaintiffs say if they had known about the lack of an antidote, they would not have used Xarelto.
    
    The first bellwether trials in the Xarelto litigation are not expected to go to court until early 2017. In a case management order (11/30/15), Judge Fallon noted that the two sides could not resolve differences concerning discovery pool plaintiffs and bellwether trial plaintiffs, and issued orders regarding how cases could be selected for inclusion in the discovery pool. The judge further noted that four cases will be selected as bellwether cases but did not issue an order on selecting bellwether trial cases.
    
    Xarelto’s maker, Janssen Pharmaceuticals, maintains the drug is not unreasonably dangerous and the drug’s warnings are adequate.

    https://www.lawyersandsettlements.com/articles/xarelto/xarelto-lawsuit-death-bleeding-issue-32-21159.html#.Vo6g3fkrJD8
    

    Return to headline | Return to top

36. Xarelto Stomach Bleed Lawsuit Claims Manufacturers Failed To Recommend Blood Monitoring

    Dec 31, 2015 | AboutLawsuits.com

    By Irvin Jackson

    A lawsuit recently filed against Bayer Healthcare and Johnson & Johnson’s Janssen subsidiary suggests that individuals nationwide may have been severely injured or died from the bleeding side effects of Xarelto due to the drug makers’ failure to provide adequate warnings about the importance of blood monitoring.

    In a complaint (PDF) filed in the U.S. District Court for the Eastern District of Louisiana, Sharon McNamee indicates that she suffered a severe stomach bleed on Xarelto because the drug makers failed to adequately warn consumers and the medical community about the dangers, including the importance of blood monitoring, making dose adjustments and taking twice daily doses.

    McNamee began taking the new-generation anti-coagulant Xarelto in November 2013, but on March 11, 2014 and again on April 2, 2014, she suffered gastrointestinal bleeding events that she indicates were life-threatening and left her with permanent injuries. As a result of the bleeding problems, McNamee indicates that she stopped using the drug in April 2014.

    Xarelto Blood Monitoring Should Have Been Recommended

    Xarelto (rivaroxoaban) was introduced in 2011 as a superior replacement for Coumadin (warfarin), which has been the go-to-anticoagulant treatment for prevention of deep vein thrombosis and pulmonary embolism for decades.

    The medication quickly became one of the top-selling drugs in the United States, as the drug makers aggressively marketed Xarelto as easier to use than warfarin, indicating that it did not require close blood monitoring to maintain the appropriate and safe dose.

    McNamee points out in the complaint that Xarelto was promoted as a single dose pill that does not require measuring patient’s blood plasma levels or any diet limitations, marketing that as the “Xarelto Difference.” However, the lawsuit alleges that clinical studies have shown that Xarelto is safer and more effective when there is blood monitoring, dose adjustment and twice a day dosing.

    “The use of Xarelto without appropriate blood monitoring, dose adjustment and twice a day dosing can cause major, life-threatening bleeding events,” the lawsuit states. “Physicians using Xarelto have to be able to balance the dose so that the blood is thinned enough to reduce the risk of stroke, but not thinned so much as to increase the risk for a major bleeding event. The Defendants were aware of this risk and the need for blood monitoring but have failed to disclose this vital health information to patients, doctors and the FDA.”

    Xarelto also lacked a safe and effective antidote at the time it was introduced, which McNamee indicates was not adequately disclosed to doctors. While the blood thinning effects of warfarin can be quickly reversed, there was no Xarelto reversal agent available to allow doctors to stop severe bleeds that may develop among users.

    During the first full year Xarelto was on the market, McNamee’s complaint notes that the drug generated more than 2,000 severe adverse event reports submitted to the FDA, including 151 deaths. Those numbers continued to climb in 2013, when Xarelto passed its competitor Pradaxa as the drug most associated in the U.S. with severe adverse health events.

    “Despite the clear signal generated by the SAE data, Defendants did not tell consumers, health care professionals and the scientific community about the dangers of Xarelto, nor did Defendants perform further investigation into the safety of Xarelto,” the lawsuit states.

    Status of Xarelto Litigation

    McNamee’s case joins hundreds of similar Xarelto bleeding lawsuits filed by individuals throughout the U.S., which each raise similar allegations that inadequate warnings were provided for consumers and the medical community.

    There are currently more than 2,400 related claims pending in the federal court system, which have been consolidated for pretrial proceedings as part of an MDL, or multidistrict litigation

    The cases are centralized before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana for coordinated discovery and a series of bellwether trials to help gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout the litigation.

    A series of Xarelto bellwether trials are expected to begin during the first half of 2017. While the outcomes of these trials will not be binding on other cases, they will be closely watched by those involved in the litigation and may help facilitate eventual Xarelto settlements to resolve large numbers of claims without the need for several thousand individual jury trials nationwide.

    http://www.aboutlawsuits.com/xarelto-stomach-bleed-lawsuit-91996/#sthash.xS6ezvLO.dpuf
    

    Return to headline | Return to top

37. Granddaughter Files Xarelto Lawsuit After Her Grandmother Dies of Bleeding

    Dec 31, 2015 | The Legal Examiner

    By Roopal Luhana

    On November 12, 2015, a Louisiana resident filed a new Xarelto lawsuit in the Eastern District of Louisiana, the current location of the consolidated Xarelto MultiDistrict Litigation (“MDL”).

    The plaintiff blames Xarelto for her grandmother’s death, and seeks in excess of $75,000 in damages from Xarelto manufacturers Janssen Pharmaceuticals, parent company Johnson & Johnson (J&J), Bayer Healthcare, and related entities.

    Plaintiff Blames Xarelto for Her Grandmother’s Death

    According to her complaint, the plaintiff’s grandmother started taking Xarelto around September 2014 for treatment of her deep vein thrombosis (DVT). The FDA approved Xarelto for this use in 2012. DVT is a condition in which the patient is at risk for a blood clot developing in the deep veins of the legs. The clot can cause inflammation and discomfort, and may travel from the legs back to the lungs, where it can cause a pulmonary embolism (PE), a dangerous clot in the lung.

    According to the complaint, the plaintiff’s grandmother took the medication as directed by her doctor. Just a couple months after starting it on November 12, 20145, she ended up in the hospital with an intracranial bleed. This means that she had bleeding around or within the brain, which can be a life-threatening situation, and can also be qualified as a stroke.

    Doctors were unable to stop the bleeding and the plaintiff’s grandmother died two days later, on November 14, 2014. The plaintiff alleges that it was Xarelto that caused the uncontrollable bleeding and death.

    FDA Reviewers Question Once-a-Day Dosing

    The plaintiff notes that Xarelto was granted FDA approval for the treatment of DVT based on clinical trials that tested the drug against a placebo. Xarelto was found to be an option for the treatment of the condition, but also presented an increased risk of bleeding events.

    The defendants promoted Xarelto as a way to reduce the risk of clots and PE in patients with DVT, but failed to provide adequate warnings about the risks of internal bleeding, particularly gastrointestinal bleeding that required transfusion. They also positioned Xarelto as a better alternative to warfarin, the leading antiocoagulant for decades, because it didn’t require dietary adjustments or blood monitoring.

    The Institute for Safe Medicine Practices (ISMP) noted in their QuarterWatch publication, however, that even during the approval process, some FDA reviewers questioned the convenient once-a-day dosing system, since studies showed peaks and troughs in the drug’s activity that could be eliminated with twice-a-day dosing.

    The plaintiff also notes in her complaint that Xarelto has no readily available antidote, which makes the risk of internal bleeding even more dangerous. Whereas patients taking warfarin can be treated with vitamin K injections to start blood clotting again, patients taking Xarelto just have to “wait it out” until the drug clears from the system.

    Xarelto the Subject of Over 2,000 Medwatch Reports

    The plaintiff also asserts the defendants overstated the benefits of Xarelto in their promotional materials—materials that both her grandmother and her grandmother’s doctor became aware of prior to the date her grandmother starting the drug. These materials suggested that Xarelto was just as effective as warfarin yet was more convenient, without emphasizing that there was no reversal agent to stop or control bleeding in patients.

    Notably, by the end of the 2012 fiscal year, the FDA Medwatch program had received over 2,000 reports of adverse events associated with Xarelto. Of those, 151 resulted in death.

    http://westvirginia.legalexaminer.com/fda-prescription-drugs/granddaughter-files-xarelto-lawsuit-after-her-grandmother-dies-of-bleeding/
    

    Return to headline | Return to top

38. Xarelto Bleeding Lawsuit Filed By Widow

    Jan 1, 2016 | Top Class Actions

    By Robert J. Burns

    A widow filed a Xarelto lawsuit alleging uncontrolled bleeding caused by the drug cost her husband his life.

    Plaintiff Carol M. of Roswell, Georgia filed the lawsuit, alleging her husband, Ralph M. died after taking Xarelto.

    According to the Xarelto lawsuit, Ralph M. took Xarelto from June 2012 until his death in March 2013 when he suffered an intracranial hemorrhage, or bleeding in the brain.

    Ralph was prescribed Xarelto to decrease his risk of suffering a stroke. Xarelto is a type of drug called an anticoagulant or blood thinner. Anticoagulants like Xarelto are intended to reduce the risk of developing dangerous blood clots within the body.

    When the clotting process misfires, a person can suffer a deep vein thrombosis, or DVT. Parts of this clot can break off and drift through the circulatory system until they get stuck and block blood vessels.

    Drugs like Xarelto reduce this risk by making it harder for blood to clot in the first place. But Xarelto lawsuits like this one allege that sometimes Xarelto works too well.

    All anticoagulants carry the risk of working too well, and making it dangerously easy to bleed to death. In extreme cases, a person taking anticoagulants like Xarelto may not be able to stop bleeding from minor injuries, including minor internal injuries.

    For example, a tiny injury to the lungs could cause a life-threatening pulmonary bleeding, or a brain injury could cause a dangerous brain bleed, like the one that took the life of Ralph.

    One contention in the Xarelto bleeding lawsuit is that at the time of Ralph’s death, there was no known reversal agent for Xarelto. Older anticoagulants like Warfarin have known reversal agents.

    In the case of Warfarin, if a patient suffers uncontrollable bleeding, doctors can administer a large dose of Vitamin K. This effectively turns off the drug. But Xarelto has no known antidote or reversal agent. The Xarelto lawsuit also asserts that there was no warning about the lack of an antidote for Xarelto, and only a brief reference to this in the overdose section of the drug information.

    Carol’s Xarelto lawsuit asserts that in spite of the risk of bleeding and the lack of an antidote, the makers of Xarelto aggressively promoted the drug, spending millions advertising Xarelto.

    During the year Ralph died, drug makers spent $11 million on advertising in journals. The Xarelto lawsuit states that in terms of dollars spent and pages bought, Xarelto was the most advertised pharmaceutical product in the world.

    The Xarelto Lawsuit is Civil Action No. 0825, within the larger Xarelto MDL In RE: Xarelto (Rivaroxaban) Products Liability Litigation, MDL No. 2592, filed in the United States District Court for the Eastern District of Louisiana.

    http://topclassactions.com/lawsuit-settlements/lawsuit-news/256495-xarelto-bleeding-lawsuit-filed-by-widow/
    

    Return to headline | Return to top

39. Xarelto Lawsuit: Blood Thinner Caused Life Threatening Bleeding Event

    Jan 4, 2016 | Top Class Actions

    By Robert. J. Burns

    Another Xarelto lawsuit has joined the ongoing litigation over alleged Xarelto bleeding events.

    In this Xarelto lawsuit, Plaintiff Edward P. of New Jersey alleges that Xarelto caused life-threatening side effects.

    As there is already a massive Xarelto legal actionworking its way through the courts, Edward P.’s counsel has filed a short form complaint, incorporating the allegations of the larger Xarelto long form that is common to all cases within the larger Xarelto MDL. As such, the short form is sparse on details about Edward P.’s individual complaints.

    In a draft of the Long Form Complaint, plaintiffs make accusations that Xarelto is a dangerous drug, and can lead to Xarelto bleeding incidents.

    Xarelto is an anticoagulant or blood thinner, a drug designed to help reduce the risk of developing stroke and pulmonary embolism, medical emergencies where a blood clot forms in the body and blocks the blood vessels that feed vital organs.

    Patients with deep vein thrombosis and some other clotting issues are at higher risk of developing such conditions, so are often prescribed Xarelto. But Xarelto lawsuits allege that the drug may work too well.

    The draft of the long form complaint holds that the earliest clinical trials for Xarelto, the ones used to get the drug’s FDA approval, “were flawed in design and conducted in a negligent manner.” According to the form, despite concerns including “unauthorized unblinding, falsification, and concerns regarding improprieties in randomization,” Xarelto was ultimately approved by the FDA.

    The long form also stated that another study, ROCKET AF, which compared Xarelto to older drugs like Warfarin “was the worst managed warfarin [sic] study group in any previously reported clinical trial involving warfarin.”

    The Xarelto MDL goes on to allege that thousands of reports of serious bleeding events have been filed with the FDA, including dozens, if not hundreds of deaths once the drug reached the market.

    Per the text of the long form draft, in 2012 alone there were 2,081 reports of Serious Adverse Events filed with the FDA, including 151 deaths, compared with 56 deaths reported among Warfarin users.

    The long form draft of the Xarelto MDL holds that the companies that made and sold Xarelto “failed to investigate, research, study, and define, fully and adequately, the safety profile of Xarelto,” and that they “failed to provide adequate warnings, about the true safety risks associated with the use of Xarelto.”

    On top of this, the architects of the Xarelto lawsuit allege that the makers of Xarelto, Janssen Pharmaceuticals, marketed the drug as not requiring the dose adjustments, twice daily dosing, and blood monitoring required for Warfarin, despite evidence that these practices could protect patients.

    The Xarelto lawsuit contends that the makers of the drug spent at least $11 Million on part of their marketing campaign in 2013 alone; the company made billions in Xarelto sales. The Xarelto lawsuit holds that these sales were partly generated by “aggressive marketing efforts” based on “flawed science.”

    The Xarelto Lawsuit is In Re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL No. 2592, filed in the U.S. District Court for the Eastern District of Louisiana.

    http://topclassactions.com/lawsuit-settlements/lawsuit-news/238756-xarelto-lawsuit-joins-large-xarelto-mdl/
    

    Return to headline | Return to top

40. Stopping Xarelto Suddenly Could Clot Your Brain

    Jan 4, 2016 | Xarelto Lawsuit Information

    New research shows that patients that stop Xarelto treatment, suddenly are at a high risk of blood clots inside their brain or lungs. A blood clot in the brain can result in paralysis of the body – and can be lethal. Xarelto is a very dangerous medication, mostly because the lack of an antidote makes every single bleeding accident a potential threat to a patient’s life. Xarelto cannot be flushed out from a patient’s body through dialysis, and due to the “once daily” dosage, there’s no way to reduce or adjust the actual dose taken by a patient. What’s worse, however, is that even a mandatory sudden stop in treatment required during a bleeding accident may significantly endanger a patient’s health.

    Researchers that participated in this study reviewed nationwide information in many registers about patients treated with blood thinners. They examined the national medical registers looking for the various causes of death, and for the incidence rate of thrombo-embolic events caused by prescription medications. These registers contained many details about the various patients treated with the given blood thinners, their doses, as well as the underlining conditions suffered by those patients and the causes of their deaths.

    Statistics showed a relevant percentage of blood clots for every 1,000 patients during and after treatment with Xarelto. The numbers found in the study demonstrated a significant increase in the quantity of blood clot events soon after the patients stopped taking their medication.

    “Our assignment was to analyze what happens to patients who run out of medication or who break off their treatment for other reasons,” says Dr. Torp-Pedersen. “By correlating the data in these types of registers we could observe that these patients have a substantial risk for a blood clot in the brain after a break or in the ending of their treatment.”

    The number of blood clots grew by 300 percent during the first 90 days after the treatment, stabilised after 180 days, then fell gradually in later times.

    Xarelto was created as a replacement of warfarin as a none needing blood monitoring medication for Atrial fibrillation. It is utilized to prevent blood clots and in specific cases, patients that are bedridden for an extended period where known to benefit. Atrial fibrillation is the most frequent irregular heartbeat and results from a disruption in the heart’s electrical system. Typical symptoms are tiredness, breathing difficulties and palpitations.

    https://xareltolawsuits.net/xarelto-side-effects-a-truly-dangerous-medication/stoping-xarelto-suddenly-could-clot-your-brain/
    

    Return to headline | Return to top

41. Study Suggests Xarelto Presents Greater Risk for Kidney Patients

    Jan 6, 2016 | Drug Reporter

    By Sarah May

    According to recently-released research findings, next-generation blood-thinning drug Xarelto may pose additional risk to patients who are already suffering from kidney disease. The study, based on data taken from the Department of Defense electronic medical records system, found that those with existing kidney ailments were significantly more likely toexperience dangerous internal bleeding while taking the drug than patients without such a condition.

    These findings raise safety concerns surrounding the blood thinner, which have already formed the basis of numerousXarelto lawsuits pending in court.

    Details of Xarelto study

    The authors of this study, presented at a meeting of the American Heart Association, examined medical data aggregated from over 44,000 patients, 6,921 of whom had previously been diagnosed with kidney disease. Of those individuals who also used the blood thinning drug Xarelto, 312 experienced significantinternal bleeding events.

    The 36,891 patients within the study who did not have existing kidney disease and who also used Xarelto registered 981 such bleeding incidents. While the findings reveal a heightened risk of bleeding for kidney patients taking the drug as compared to those without renal problems, the bleeding events were not found to be linked to a higher rate of death as a result.

    It is also worth noting that patients suffering from both kidney disease and heart trouble demonstrated an even higher likelihood of a major bleeding event than patients with kidney disease alone.

    Findings underscore growing concerns about Xarelto

    The potential dangers of Xarelto side effects has been the topic of research and litigation in recent months. Brought to the American market in 2011, Xarelto (rivaroxoban) was touted as a breakthrough,next-generation anticoagulant medication designed for individuals at heightened risk of pulmonary embolism or deep vein thrombosis. The drug was hailed as being far superior to predecessor blood thinner warfarin, which had long been the standard option for large numbers of patients.

    Xarelto was represented as being a more convenient choice in that it did not require the sort of ongoing medical monitoring necessary for patients taking warfarin. However, a primary drawback of Xarelto has always been the absence of an antidote that could reverse its blood-thinning effects in the event of a serious bleed. In contrast, the effects of warfarin have always been reversible in relatively short order with an appropriate dose of Vitamin K.

    Wave of Xarelto litigation continues

    In December of 2014, all federal lawsuits relating to Xarelto related bleeding events and deaths werecentralized into multidistrict litigation (MDL) in the Eastern District of Louisiana under the supervision of Judge Eldon Fallon. The purpose of this type of consolidation is to streamline pretrial proceedings, achieve judicial economy and facilitate consistency of evidentiary and other rulings prior to the commencement of trials.

    Plaintiffs in Xarelto lawsuits are alleging that drug makers Janssen and Bayer committed numerous acts of negligence in bringing the blood thinner to the American market, alleging defective manufacturing and design, failure to warn physicians and consumers of known risks, misrepresentation, fraud, breach of warranties and violation of consumer protection laws.

    Individuals harmed by Xarelto, including the families of those who suffered fatal bleeding events, areseeking significant financial damage awards as compensation for medical expenses, pain, suffering, emotional distress and other harm sustained.

    http://drugreporter.com/2016/01/study-suggests-xarelto-presents-greater-risk-kidney-patients/
    

    Return to headline | Return to top

42. Judge For Xarelto Bleeding Lawsuit Claims Advises On Case Selection For Bellweather Trials

    Jan 6, 2016 | Southern Med Law

    The federal judge presiding overXarelto bleeding lawsuit claims has developed the process for selecting Xarelto cases for discovery and bellwether trials. The federally filed Xarelto bleeding side-effects lawsuits against Bayer HealthCare and Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit, allege that the Xarelto blood thinner causes brain bleeds and internal bleeding episodes that result in hospitalization for transfusion or death. (In Re: Xarelto Products Liability Litigation, No. 2592)

    U.S. District Judge Eldon Fallon said in a Case Management Order issued on November 20, that he developed the plan since attorneys for the plaintiffs and defendants were unable to resolve their disputes over how the cases should be selected. Under Judge Eldon’s plan, plaintiffs’ attorneys will select 10 cases and defendants’ attorneys will select 10 cases, and the remaining 20 cases will be selected randomly. Of the 40 Xarelto cases,

    • 20 will originate from the U.S. District Court, Eastern District of Louisiana
    • 4 will originate from the federal district in Mississippi
    • 2 will originate from the federal district in Texas
    • 7 will come from a federal district in any of seven states chosen by plaintiffs
    • 7 cases will come from a federal district in any of seven states chosen by defendants

    The CMO directed both parties to develop a plan before June 10, 2016 to select four cases, from the 40-case discovery pool, for bellwether trials. The parties are to submit their proposed case selection plan to the court by July 1, 2016. (In Re: Xarelto Products Liability Litigation, No. 2592)

    “We are pleased with Judge Eldon’s decision to develop a case-selection plan so that the Xarelto litigation can continue to move forward,” says Dr. François Blaudeau, the founder of Southern Med Law.

    As both an attorney and practicing physician, Southern Med Law’s Dr. François Blaudeau possesses a unique understanding of the medical and legal questions relating to Xarelto lawsuits. If you or a loved one experienced life-threatening internal bleeding or other complications allegedly associated with Xarelto, please contact the Firm as soon as possible to learn more about your legal rights. You can arrange for a free, no obligation Xarelto lawsuit review by calling Southern Med Law today, at 205-547-5525.

    Xarelto is a prescription blood thinner approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of strokes, deep vein thrombosis, pulmonary embolism, and blood clots in patients who have undergone hip or knee replacement surgery. Xarelto is also approved to prevent blood clots in patients with atrial fibrillation. The FDA considers Xarelto a new generation anticoagulant compared to warfarin, a blood thinner that has been sold since 1954. Xarelto, however, does not have an approved antidote to treat internal bleeding whereas warfarin uses vitamin K as an antidote for any bleeding side effects, according to the FDA.
    [fda.gov/Drugs/NewsEvents/ucm405148.htm, July 17, 2014]
    [fda.gov/downloads/Drugs/DrugSafety/UCM280333.pdf, FDA, June 2015

    All federally filed Xarelto bleeding side-effects lawsuit claims were centralized in December 2014 in the U.S. District Court, Eastern District of Louisiana for coordinated pretrial proceedings. The potential cases selected for bellwether trials will go through a discovery process in which plaintiffs and defendants exchange evidence and information about the claims. Bellwether jury trials serve as “test trials” and provide insight into how similar Xarelto claims could be decided. Judge Fallon has scheduled the first bellwether trial for February 6, 2017, and the next three trials for March 13, 2017, April 24, 2017 and May 30, 2017. (In Re: Xarelto Products Liability Litigation, No. 2592)

    Throughout his career, Dr. Blaudeau has worked hard to develop a strong reputation in healthcare litigation. His first-hand knowledge of medicine has made the Southern Med Law team an aggressive and effective advocate for those who were harmed due to negligent pharmaceutical companies. If you or a loved one where harmed by Xarelto, please contact Southern Med Law today to learn more about your legal rights. Call today for a free, no obligation Xarelto lawsuit review by filling out our online form, or by calling the office directly at 205-547-5525.

    https://www.southernmedlaw.com/judge-for-xarelto-bleeding-lawsuit-claims-advises-on-case-selection-for-bellweather-trials/2487
    

    Return to headline | Return to top

Full Text of Stories Below